

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Relaxation for Critically ill Patient Outcomes and Stress-coping Enhancement (REPOSE): A protocol for a pilot randomized trial of an integrative intervention to improve critically ill patients' delirium and related outcomes

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023961
Article Type:	Protocol
Date Submitted by the Author:	04-May-2018
Complete List of Authors:	Papathanassoglou, Elizabeth; University of Alberta, Faculty of Nursing Skrobik, Yoanna; McGill University, Medicine Hegadoren, Kathleen; University of Alberta, Faculty of Nursing Thompson, Patrica; 3. Royal Alexandra Hospital, Edmonton, AB, Canada, Critical Care Medicine Stelfox, Henry; University of Calgary, Critical Care Medicine Norris, Colleen; University of Alberta, Faculty of Nursing Rose, Louise; University of Toronto, Lawrence S. Bloomberg Faculty of Nursing Bagshaw, Sean; University of Alberta Meier, Michael; University of Alberta LoCicero, Cheryl Ashmore, Rhonda Sparrow Brulotte, Tiffany ; University of Alberta Hassan, Imran; University of Alberta, EPICORE Park, Tanya; University of Alberta, Faculty of Nursing Kutsogiannis, Demetrios J; University of Alberta, 2. Department of Critical Care Medicine, Faculty of Medicine and Dentistry
Keywords:	critical illness, music therapy, relaxation, guided imagery, delirium, complex intervention

SCHOLARONE™
Manuscripts

Relaxation for Critically ill Patient Outcomes and Stress-coping Enhancement (REPOSE):

A protocol for a pilot randomized trial of an integrative intervention to improve critically ill patients' delirium and related outcomes

Elizabeth D.E. Papathanassoglou, RN, PhD^{1*}, Yoanna Skrobik, MD FRCP(c) MSc FCCP⁴, Kathleen Hegadoren, RN, PhD¹, Patrica Thompson, RN, CCRP³, Henry T. Stelfox, MD, PhD⁵, Colleen Norris, RN, PhD¹, Louise Rose, RN, PhD^{6,7}, Sean Bagshaw, MD, PhD^{2,8}, Michael Meier, MD, PhD^{2,8}, Cheryl LoCicero, BSc⁹, Rhonda Ashmore, MScPT¹⁰, Tiffany Sparrow Brulotte, MTA¹¹, Imran Hassan, MSc¹², Tanya Park, RN, PhD¹, Demetrios J. Kutsogiannis MD MHS FRCPC^{2,3}

1. University of Alberta, Faculty of Nursing, Edmonton, AB, Canada
2. Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
3. Royal Alexandra Hospital, Edmonton, AB, Canada
4. Department of Medicine, McGill University; Regroupement de Soins Critiques Respiratoires, FRQS
5. Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
6. Sunnybrook Health Sciences Centre, Toronto, ON, Canada
7. King's College London, London, UK
8. University of Alberta Hospital, General Systems ICU, Edmonton, AB, Canada
9. Registered Massage Therapist (RMT), Certified Advanced Rolfer
10. Registered Massage Therapist (RMT), PT
11. Accredited music therapist (BMT, MTA), MA candidate in ethnomusicology
12. Biostatistician, EPICORE Centre, University of Alberta

(*): To whom correspondence should be addressed.

Key words: critical illness, music therapy, relaxation, guided imagery, autonomic nervous system, delirium, complex intervention

Word count: 3,583

Correspondence: Elizabeth D. E. Papathanassoglou, University of Alberta, Faculty of Nursing, 5-262 Edmonton Clinic Health Academy (ECHA), 11405-87th Ave. Edmonton, Alberta, Canada T6G 1C9, Tel.: (780) 492-5674 (w), (780) 237-9375 (c), e-mail: papathan@ualberta.ca

Abstract

Introduction: Delirium is a common complication of critical illness, associated with negative patient outcomes. Preventive or therapeutic interventions are mostly ineffective. Although relaxation-inducing approaches may benefit critically ill patients, no well-designed studies target delirium prevention as a primary outcome. The objective of this study is to assess feasibility and treatment effect estimates of a multimodal integrative intervention incorporating relaxation, guided imagery, and moderate pressure touch-massage for prevention of critical illness delirium and for related outcomes.

Methods and analysis: Randomized, controlled, double-blinded trial with 2 parallel groups (1:1 allocation: intervention and standard care) and stratified randomization [age (18-64, ≥ 65), presence of trauma) with blocking, involving 104 patients with Intensive Care Delirium Screening Checklist (ICDSC): 0-3 recruited from 2 academic ICUs. Intervention group participants receive the intervention in addition to standard care for up to 5 consecutive days (or until transfer/ discharge); control group participants receive standard care and a sham intervention. We will assess pre-defined feasibility outcomes, i.e., recruitment rates, protocol adherence. The primary clinical outcome is incidence of delirium (ICDSC ≥ 4). Secondary outcomes include pain scores, inflammatory biomarkers, heart rate variability, stress and quality of life (6 weeks; 4 months) post-ICU discharge. Feasibility measures will be analyzed descriptively, and outcomes longitudinally. Estimates of effects will be calculated.

Ethics and dissemination: The study has received approval from the Human Research Ethics Board, University of Alberta. Results will inform the design of a future multi-center trial.

Registration: clinicaltrials.gov (NCT02905812).

Protocol date: March 3, 2018, version 5, Protocol amendment number: 07

Primary reasons for amendment: Refining feasibility of intervention and data collection.

Summary

Strengths and limitations of this study

- We will test feasibility and measures of effect of a previously piloted relaxation-inducing intervention for the prevention of delirium and improvement of related outcomes in critically ill patients.
- We will employ an evidence-based, non-pharmacological multimodal integrative intervention that has shown effectiveness for reducing pain and improving a number of secondary outcomes in a previous pilot study.
- This pilot aims to assess estimates of effect and feasibility to inform a future trial.
- Although clinicians and outcome assessors will be blinded, due to the nature of the intervention, participants and nurses providing direct care to patients cannot be blinded to allocation, although they will be blinded to the study hypotheses.
- The mechanisms of effects of relaxation-inducing interventions in critical illness are not well understood; hence, we aim to explore effects of the intervention on parasympathetic system activation and inflammatory markers.

Introduction

ICU delirium affects 35-55% of critically ill patients, and is independently associated with a 13-fold (adjusted odds ratio (OR):4.88-13.0) increased risk of death (1). ICU delirium carries important financial and societal burdens [(39% higher adjusted ICU (95% CI:12-72%), and 31% higher hospital costs (95% CI:1-70%)] (2). Moreover, patients identify frightening delirium experiences and pain as the most severe stressors (3,4) in critical care. Pharmacological interventions for the prevention and treatment of delirium have limited benefit and are associated with high costs and risks for side effects (5, 6). Although clinical guidelines recommend the development of non-pharmacologic interventions to prevent delirium (7), effective prevention strategies have yet to be established (8).

A prolonged and eventually aberrant stress response and depressed parasympathetic (PNS) activity have been postulated as the pathophysiological basis for the development of both ICU delirium and systemic inflammation (9-12). Frightening hallucinations and ideations during delirium may further exaggerate the stress-response and prolong critical illness with detrimental consequences. Pain may worsen matters by reciprocal incremental feed-back on inflammation and stress (3, 13). Thus, in critical illness, stress, delirium, pain and systemic inflammation may comprise a self-perpetuating syndrome. Attenuating the cascade of negative health impacts from pain and delirium has become a high clinical priority (Fig. 1) (7). Moreover, the growing recognition that delirium and other critical illness sequelae may have long term consequences in critical illness survivors (14) further highlights the need for prevention strategies.

Animal models illustrate that PNS stimulation and acetylcholine (ACh) release suppress inflammation and decrease fatality, via the cholinergic anti-inflammatory pathway (15). Devising ways to draw on the autonomic nervous systems' inflammation- and stress-regulatory properties

1
2
3 by non-pharmacological interventions has the potential to improve outcomes with low side-effect
4 risk. However, stimulation of the PNS in critical care is challenging. Relaxation-inducing
5
6
7 interventions can induce PNS activity. Such approaches have successfully been used in diverse
8
9
10 patient populations to counter stress, but remain under-tested in critical illness (16). A recent
11
12
13 systematic review shows favorable effects of relaxation and guided imagery intervention in
14
15
16 reducing pain, anxiety and length of stay in critically ill patients (17) In a pilot randomized
17
18
19 controlled trial (RCT) of the effects of a similar multi-modal intervention on the incidence of
20
21
22 pain and on a number of secondary outcomes, we observed significant decreases in pain
23
24
25 incidence (RR=0.56, p=0.003) and severity (p<0.0001), systolic arterial pressure, anxiety, along
26
27 with improved sleep quality (18).

28 29 30 **Hypothesis**

31 We hypothesize that a multimodal intervention incorporating relaxation and guided imagery
32
33
34 (RGI) and moderate pressure touch-massage is feasible within a critical care setting and can have
35
36
37 an effect in decreasing delirium incidence and duration, and in improving physiological and
38
39
40 psychological outcomes in randomized critically patients who will receive the intervention
41
42 compared to patients receiving standard care plus a sham intervention only.

43 44 45 **Design and Methods**

46 47 48 **Study design**

49 Relaxation for Critically ill Patient Outcomes and Stress-coping Enhancement (REPOSE) is a
50
51
52 pilot feasibility, randomized, controlled, double-blinded trial with 2 parallel groups (intervention
53
54
55 and standard care). Accounting for major risk factors of delirium (13), stratified randomization
56
57
58

1
2
3 according to age (18-64, ≥ 65) and presence of either surgical or trauma injury with blocking and
4
5 1:1 allocation to assure balance in numbers per group will be employed.
6
7

8 **Research Objectives**

9
10
11 Research objectives include to:

- 12
13
14 a) Assess clinical trial feasibility with pre-defined goals (enrolment, randomization, adherence,
15 timing of intervention, workload)
16
17
18 b) Calculate estimates and variance of treatment effect across outcome measures
19
20
21
22 c) Calculate Confidence Intervals (CI) of incidence proportions, means and Standard Deviation
23 (SD) of outcome measures in study groups, and
24
25
26
27
28 d) Explore the feasibility of identifying underlying physiological mechanisms
29
30

31 **Setting, recruitment and sample size:**

32
33
34 Consecutive patients admitted to 2 academic ICUs, in Edmonton, AB, Canada, with an ICDSC
35 score of 0-3 will be screened for study eligibility and will be recruited by research staff at each
36 site. In cases where an ICDSC score cannot be obtained on admission, we will screen patients for
37 up to 4 days after admission. Since delirium occurs most often within 5 days of admission,
38 screening and enrolment will take place as soon as possible and within 96 hours after ICU
39 admission. This pilot is not powered to determine a difference in a primary outcome, since we
40 aim to assess estimates of effect. For a definitive trial, we would require 290 (145/arm) patients
41 to detect a 10% difference in incidence proportion between intervention (20%) and control
42 (30%) arm (two-sided $\alpha=0.05$, power=80%, drop-out rate=10%). The Pan method (19),
43 which is based on generalized estimating equations, was used to perform the sample size
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REPOSE 6

1
2
3 calculation under the assumption of AR(1) correlation structure among 5 days repeated
4 measurements with correlation between any two adjacent observations from the same subject of
5
6 0.5. Since this is a pilot, aiming to explore feasibility and estimates of effects, and the incidence
7
8 rates used for the calculation might not be appropriate, we used 36% of the sample size of the
9
10 full study to estimate the parameters accurately and get an experience for a full trial (20).
11
12
13

14 15 **Eligibility:**

16 Inclusion criteria: a) Age over 18 years, b) ICDSC:0-3.

17
18 Exclusion Criteria: Patients: a) Already in the ICU for more than 96 hours, b) with ICDSC>3
19
20 within 72 h of screening in case intervention has not been initiated, c) on special contact
21
22 precautions (i.e., MRSA, VRE, HIV), d) with expected Intensive Care Unit (ICU) Length of stay
23
24 (LOS) < 72 hours, e) with acute neurological illness/ neurological trauma, persistent deep
25
26 sedation or coma [Richmond Agitation Sedation Scale (RASS = -4, -5)] f) with current history of
27
28 severe mental health problems and dementia, as per history, g) with hearing impairment or
29
30 conditions not permitting use of headphones, h) on neuro-muscular blockers, i) with known or
31
32 suspected substance/ alcohol withdrawal, and j) enrolled in trials of sedatives, antipsychotics.
33
34
35
36
37
38
39
40

41 **Intervention**

42
43 The choice of a multimodal intervention (duration: 55min) is based on an evidence-based
44
45 literature review, its superiority to unidimensional approaches (21), the recommendations of the
46
47 American Holistic Nurses Association (22) and a successful pilot (18). The intervention has
48
49 been developed by the research team and a group of experts based at the University of Alberta
50
51 and Cyprus University of Technology. It includes: a) a brief moderate pressure massage session
52
53 (massage: 15 minutes), b) relaxation and guided imagery (30 minutes, through headphones). The
54
55
56
57
58
59
60

REPOSE 7

1
2
3 30 min recorded RGI intervention involves: a) guided relaxation, b) a structured guided imagery
4 script supported by instrumental music, and c) recorded instrumental music for 15 minutes (60
5 beats per min approximately). Moderate pressure (4 N, approximately or patient pressure rating
6 3/10) low velocity (1-5cm/second) massage consists of broad and repetitive circular movements
7 with wide area of contact, applied sequentially for 2-3 minutes at each site: hands, forearms,
8 lateral arms, and then over trapezius muscles, the temple, scalp, face and forehead area. Areas
9 are to be contacted as appropriate to each participant, and the protocol may be adapted taking
10 into account safety issues (i.e., to avoid area around intravascular catheter or injury). Moderate
11 pressure massage is involved in PNS activation, in contrast to light pressure (23). The
12 intervention will be administered once daily (09:00-15:00) for up to 5 consecutive days by
13 trained research staff not involved in patient care, who will be randomly audited by the Trial
14 Steering Committee (TSC) to ensure protocol compliance. Deviations from the intervention
15 protocol will be recorded in detail. The intervention will be terminated upon a patient's transfer
16 or discharge from the ICU. The intervention may be discontinued in case of adverse events
17 related to the intervention or withdrawal of consent.

38 **Randomization and concealment**

39
40
41 Participants will be randomly assigned to either control or intervention (1:1 allocation) as per a
42 computer-generated randomization schedule, generated by the Epidemiology Coordinating
43 Research Centre (EPICORE), University of Alberta (UofA), stratified by site, age (18-64, ≥ 65),
44 and presence of surgery or trauma using permuted blocks of random sizes. The block size will
45 not be disclosed to ensure concealment. After baseline measurements, allocation will be
46 disclosed only to the intervention staff. Codes will be generated prior to the beginning of the
47 study by EPICORE.

Blinding

Investigators, physicians and nurses (when possible), outcome assessors, research assistants, and laboratory technicians will be blinded to group allocation during the trial and analysis. Due to the nature of the intervention, participants cannot be blinded to allocation. Also, participants' primary nurses cannot be blinded to study procedures (i.e., delivery of massage); however, they will remain blinded to study hypotheses, study design (i.e., numbers and types of participants' groups) and allocation will not be revealed to them. These along with the sham intervention will maintain an adequate level of blindness even among participants' primary nurses, in order to minimize bias.

Treatment arms

Patients randomly allocated to the intervention group will receive the intervention in addition to standard care. Patients allocated to the control group will receive standard care and a sham intervention consisting of presence of a research staff at the bedside with drawn curtains and silent headphones (Schematic of study design in Figure 2).

Concomitant care

Standard care will be continued for all participants. Type and dose of all administered sedative, psychoactive and analgesic medication will be recorded.

Duration of participation: The total duration may vary according to ICU length of stay and will be 17 weeks approximately, from enrolment until the last follow up at 4 months post-ICU discharge.

Data Collection and Instruments

1
2
3 Data will be collected for each participant by blinded data collectors and captured in a Research
4
5 Electronic Data Capture (RedCap) database developed and monitored by EPICORE. Time points
6
7 include: baseline measurements, follow-up while in the ICU for up to 5 days, follow up 48-96
8
9 hours after ICU discharge, follow-up 6 weeks and 4 months after ICU discharge. In case of
10
11 participants who discontinue participation, data already collected will be retained.
12
13

14
15 All study scales are routinely used in clinical practice and have established psychometric
16
17 properties. The ICDSC is one of the most reliable tools for assessment of ICU delirium
18
19 advocated by recent guidelines (3, 24). Inter-observer reliability of and sensitivity (80.1, 95%
20
21 CI:73.3-85.8) of ICDSC have been established and will be further assessed in this study (24). For
22
23 comatose, deeply sedated patients [Richmond Agitation Sedation Scale (RASS = -4, -5)]
24
25 delirium cannot be assessed. Data captured on Case Reports Forms are included in Figure 2.
26
27

28
29 Baseline data captured at enrolment will include: Sociodemographic data, admission diagnosis,
30
31 history of alcohol use, medications prior to admission, metabolic acidosis, ICDSC, RASS, Short
32
33 Form Informant Questionnaire on Cognitive Decline in the Elderly (Short IQCODE), Pre-Deliric
34
35 Delirium Risk Score, baseline IV sedation, analgesia and antipsychotic dose, disease severity at
36
37 admission (Acute Physiology & Chronic Health Evaluation II (APACHE II), Sequential Organ
38
39 Failure Assessment: SOFA), number of days in hospital and ICU prior to protocol enrolment.
40
41
42

43 **Outcome Measures**

44
45
46 Primary and secondary outcome, as well as feasibility, measures include (Appendix 1):
47

- 48
49 **A. Primary clinical outcome:** a) Incidence rate of delirium (ICDSC ≥ 4), during 5 days of
50
51 intervention. Presence of delirium will be assessed by blinded trained nurse assessors 2
52
53 times daily (8am, 8pm).
54
55

B. Secondary outcomes [Estimates, variance of effects, proportions and means, SD**(where applicable) per group]:**

1. **Delirium related secondary outcomes:** a) Incidence rate of delirium (ICDSC ≥ 4) during ICU stay and post-intervention, b) incidence rate of subsyndromal delirium (ICDSC: 1-3) during the intervention period and subsequent ICU stay, c) time to delirium occurrence, d) proportion of delirium-free time during up to 8 days of ICU stay (excluding periods with deep sedation, coma), e) Sedation levels (Richmond Agitation Sedation Scale (RASS) score, f) Daily sedative (benzo-equivalents and propofol), analgesic (morphine equivalents) and antipsychotic agent (type, mg/24 hours) dose.
2. **Pain related outcomes (Pre- and post-intervention):** a) Pain intensity (self-reported (S-R) numeric rating scale (NRS), pain indicators (Critical Care Pain Observation Tool (CPOT) in patients unable to self-report, b) perceived stress level (S-R NRS).
3. **Sleep (Daily):** a) Sleep quality (S-R NRS), b) sleep duration (in minutes) (sleep monitors and nurses' log).
4. **Disease severity (Daily):** Sequential Organ Failure (SOFA) score
5. **Physiological Biomarkers (Pre- & post-intervention):** a) Serum Inflammation biomarkers [High-mobility-group-box 1 (HMGB-1), C-reactive protein (CRP) levels, b) High (HF) and low frequency (LF) components of heart rate variability (HRV) as measures of PNS status, c) Serum ACh levels, as a measure of PNS activation.
6. **Psychological outcomes (2-7 day after ICU discharge):** Anxiety (Hospital Anxiety and Depression Scale: HADS & State Trait Anxiety Inventory-6: STAI-6)

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
7. **Clinical outcomes** (*At discharge*): a) length of ICU stay (ICU LOS) (or ward-ready), b) Duration of mechanical ventilation/ proportion of mechanical ventilation-free days, c) survival, d) hospital LOS and e) (*3 months post-ICU discharge*): 90-day survival.
 8. **Quality of life outcomes** (*6 weeks and 4 months post-ICU discharge*): EuroQol Five Dimensions Questionnaire (EQ-5DL), Short Form 36 Health Survey (SF-36)
 9. **Recollection and perception of the intervention** (*2-7 days after ICU discharge and 6 weeks post-ICU discharge*): Qualitative open-ended questions to explore recollection of intervention, views on intervention and acceptability.

24 **C. Feasibility**

- 25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1. **Enrolment & consent**: a) percentage (%) of eligible patients; reasons for non-eligibility, b) time from admission to enrolment, c) recruitment rates, d) % of patients declining consent
 2. **Randomization & concealment**: a) time from enrolment to randomization, b) % of cases at which allocation was inappropriately revealed; description of incident.
 3. **Protocol adherence & intervention fidelity**: Percentage of: a) participants completing the entire study protocol, b) sessions missed, interrupted, delayed; reasons. Adherence to intervention protocol assessed by random observation audits.
 4. **Data Collection & management**: a) timeliness, accuracy of data collection, reliability, b) testing of trial database, c) type, % of missing values, d) qualitative data on participants' perceptions of the study.

Blood sampling: One 5 ml blood sample will be collected in pre-coded general anti-coagulated vials, through an intravascular catheter already in place, within 10 min before and 10 min after the intervention.

Biomarker quantifications

- a. Serum levels of HMGB-1, ACh and CRP.

These will be quantified by commercially available sandwich enzyme-linked immunosorbent colorimetric assay (ELISA) kits (LifeSpan Biosciences, Seattle; WA, Biosource, S. Diego, CA; R & D Systems, Minneapolis, MN, respectively). Intra- and inter-assay coefficients of variation (CV) are expected to be less than 10%. All samples will be tested within the same assay run in duplicate by a specialized laboratory technician. Measurements will be carried out at the Women's Health Research Laboratory, Faculty of Nursing, University of Alberta.

- b. **ANS (Autonomic Nervous System) activity: HF, LF AND LF/HF ratio**

ANS activity will be assessed through frequency domain analysis of electrocardiographic (ECG) recordings. ECG recordings will be logged using the Zephyr™ BioModule™ and data will be imported into the OmniSense™ software. Data from OmniSense™ will then be uploaded to Kubios HRV software (Kubios HRV- Heart Rate Variability Analysis Software) and HF, LF and LF/HF ratios will be computed.

Data Analysis

Statistical Methods

Demographic/ clinical characteristics of patients and all outcomes will be presented by treatment group using descriptive statistics— mean (SD), median (IQR) or proportion. Outcomes will be

1
2
3 analyzed longitudinally over 5 days by logistic regression model based on generalized estimating
4 equations (GEE) with AR(1) correlation structure. ANCOVA, t-test or Mann-Whitney test, as
5 appropriate, will be conducted for the continuous outcomes that are not longitudinal. Chi-square
6 or exact test, as appropriate, will be used for categorical outcomes. Confidence intervals will be
7 presented with estimated effects. Primary analysis will be based on all available data utilizing
8 data from all assessments. Since GEE assumes missing completely at random (MCAR)
9 mechanism, we plan to conduct a sensitivity analysis based on inverse probability weighted GEE
10 (IPWGEE) (22) (25) which employs a less restrictive missing at random (MAR) mechanism. A
11 “last observation carried forward” (LOCF) approach was not considered because analyzing all
12 available data performs better than LOCF in GEE setting with respect to bias, Type I error rate
13 and coverage probability under both MCAR and MAR mechanisms. Analysis will be conducted
14 by EPICORE.

15
16 To account for noncompliance, protocol deviations and missing outcomes, intention-to-treat
17 (ITT) analysis will be employed. ITT analysis includes every randomized subject according to
18 treatment assignment. Additionally, per protocol analysis will also be employed. Per-protocol
19 (PP) population is defined as a subset of the ITT population who completed the study without
20 any major protocol violations. If ITT and PP analyses lead to similar conclusions the reliability
21 of results will be supported.

22 *Qualitative analyses*

23
24 Interview transcriptions will be thematically analyzed by an inductive content analysis approach
25 (26). A coding scheme will be developed based on recurrent themes of the first five interviews.
26 Subsequently, two researchers (EP, TP) will code independently, using axial and inductive
27 coding to formulate a final coding template by consensus. The final coding scheme will then be

1
2
3 used to code, compare and interpret all transcripts. Individual analyses of the team members will
4
5 be discussed to achieve shared understanding and to increase reliability. The data will be
6
7 analyzed via NVivo software (QSR International Doncaster, Victoria, Australia).
8
9

10 **Quality Control and Quality Assurance**

11
12
13 This pilot will be supervised by an independent trial steering committee (TSC), consisting of 3
14
15 clinical trial experts independent of the research team. Periodical audits of trial processes at both
16
17 sites by personnel independent from investigators will be initiated by the TSC. Randomization,
18
19 recruitment, intervention adherence, blinding, stability and data collection processes will be
20
21 monitored. Trial Monitoring Committee (TMC) will also review relevant information from
22
23 similar studies and will consider the recommendations of the Data Monitoring (DMC) and Ethics
24
25 Committee. Study personnel will be trained for standardized processes. Clinical data will be
26
27 retrieved from the quality-controlled clinical information system of the units. Detailed electronic
28
29 data collection forms with embedded quality controls will be used and reviewed in detail. Data
30
31 quality will be monitored through EPICORE before, during, and after entry. All data will be
32
33 entered electronically using study forms generated through RedCap with embedded quality
34
35 control processes. Study data will be collected and managed using REDCap electronic data
36
37 capture tools hosted at the University of Alberta (27). A quality control system will be applied
38
39 for biological measurements as per lab protocol. Day-to-day operations of the trial will be
40
41 overseen by a Trial Management Group (TMG) comprising, as a minimum, the Principal
42
43 Investigator, Senior Trial Manager, Trial Manager, Trial Statistician and Data Manager. TMG
44
45 meetings will take place on a regular basis throughout the duration of the study. The TMG will
46
47 have responsibility for ensuring the compliance and progress of the study in relation to all
48
49 regulatory, administrative academic and any clinical or safety issues.
50
51
52
53
54
55
56
57
58
59
60

Ethics

The protocol has received approval from the Human Research Ethics Board (HREB) University of Alberta and administrative approvals from participating institutions. This study will be conducted in compliance Canadian and International Good Clinical Practice standards. No deviation from the protocol will be implemented without the prior review and approval of the HREB except where it may be necessary to eliminate an immediate hazard to a research participant. In such case, the deviation will be reported to the HREB.

Experienced research personnel not involved with the delivery of the intervention and in patient care will acquire informed consent from legal surrogates. Participant assent will be acquired when participants regain capacity. Confidentiality, anonymity and right to withdraw at any point with no questions asked and no effect on the quality of care received will be assured. After completion of the study the data and samples will remain stored at the academic institution for 5 years.

Confidentiality

Code-identified encrypted study data will be stored separately from participant information at an EPICORE database permitting code-access only. All study forms, lab specimens and data will be identified by an alphanumeric code to maintain confidentiality. Records that contain names, identifiers will be stored separately from study data identified by code. Participants' information will not be released outside the study. Participant information will be stored at an encrypted limited code-initiated access electronic file. Consent forms will be kept in a locked file cabinet at a pre-specified limited-access room, University of Alberta.

Safety

Although prior pilot data did not provide evidence of adverse effects or increased rate of complications, any physiological/ behavioural alteration during interventions will be recorded and analysed. Adverse events, irrespective of causal relationship, will be collected for all participants, during and up to half an hour after the intervention.

Patient and Public involvement

The protocol is based on a pilot study with 60 randomized patients (18), 12 of which provided feedback regarding the desirability, burden and specific components of the intervention, study procedures and preferred outcomes. Participants' feedback informed the design of the study, resulting in many significant changes. Preferred post-ICU follow-up times were informed by an informal advisory group through the Alberta Innovates Strategy for Patient Oriented Research (SPOR) network of patient representatives. Moreover, as a patient and clinician engagement strategy, an advisory group with representatives of patients, families and clinicians will act as a consultation group for the research team. Acceptance and desirability will be assessed further. Recommendations will inform future development of the intervention and research design. Canadian Institutes of Health Research (CIHR) guidelines for patient engagement will be used to establish and facilitate the advisory group. Feedback on: a) concerns on the intervention, study processes, b) desirability of intervention (massage, music choices, complexity, voice of recording, pace), c) timing within the day, d) duration/ feasibility of the intervention, e) burden of study processes, f) outcomes to be addressed in the future trial, g) interpretation of results, h) strategies for dissemination of findings will be collected.

Data Dissemination

Results will be disseminated to participants, healthcare professionals, health services authorities and the public via conference presentations and publications. Results of this study will be used to inform the design and conduct of a future multi-center trial. The results of the trial will be presented at national and international meetings and published in peer-reviewed journals. A lay summary of the results will be available to trial participants on request. An online summary of the findings will also be made available.

Conclusions: This pilot clinical trial integrates a low-risk, patient-centered strategy, translational research and psychological outcomes to allow an evaluation of non-pharmacologic delirium management with mechanistic insights. Implications of the definitive trial include the potential to reassure patients, decrease the incidence of frightening delirium experiences, and improve longitudinal outcomes.

References

1. Zaal IJ, Slooter AJ. Delirium in critically ill patients: epidemiology, pathophysiology, diagnosis and management. *Drugs* 2012; 72(11):1457-71
2. Milbrandt EB, Deppen S, Harrison PL, et al., Costs associated with delirium in mechanically ventilated patients. *Crit Care Med* 2004; 32(4): 955-62.
3. Papathanassoglou E. Recent advances in understanding pain: What lies ahead for critical care? *Nurs Crit Care* 2014; 85(11):1586-93
4. Brame AL, Singer M. Stressing the obvious? An allostatic look at critical illness. *Crit Care Med* 2010; 38(10 Suppl):S600-7

- 1
2
3 5. Al-Qadheeb NS, Skrobik Y, Schumaker G, et al. Preventing ICU Subsyndromal Delirium
4 Conversion to Delirium With Low-Dose IV Haloperidol: A Double-Blind, Placebo-
5 Controlled Pilot Study. *Crit Care Med* 2016; 44(3):583-91
6
7
- 8
9
10 6. Su X, Meng ZT, Wu XH, Cui F, Li HL, Wang DX, Zhu X, Zhu SN, Maze M, Ma D.
11 Dexmedetomidine for prevention of delirium in elderly patients after non-cardiac
12 surgery: a randomised, double-blind, placebo-controlled trial. *Lancet*; 2016.
13 15;388(10054):1893-1902. doi: 10.1016/S0140-6736(16)30580-3.
14
15
16
17
- 18 7. Barr J., Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of
19 pain, agitation, and delirium in adult patients in the intensive care unit. *Crit Care Med*
20 2013; 41(1): 263-306
21
22
23
24
25
- 26 8. Trogrlić Z, van der Jagt M, Bakker J, et al. A systematic review of implementation
27 strategies for assessment, prevention, and management of ICU delirium and their effect
28 on clinical outcomes. *Crit Care* 2015 ;19:157
29
30
31
32
- 33 9. Papathanassoglou, E. D., Giannakopoulou, M., Mpouzika, M., Bozas, E., Karabinis, A.
34 Potential effects of stress in critical illness through the role of stress neuropeptides.
35 *Nursing in Critical Care* 2010; 15(4), 204-16.
36
37
38
39
- 40 10. Cuesta, J. M., Singer, M. The stress response and critical illness: A review. *Critical Care*
41 *Medicine* 2012; 40(12), 3283-9.
42
43
44
- 45 11. Norris, P. R., Ozdas, A., Cao, H., et al. Cardiac uncoupling and heart rate variability
46 stratify ICU patients by mortality: A study of 2088 trauma patients. *Annals of Surgery*
47 2006; 243(6), 804-12.
48
49
50
51
52
53
54
55
56
57

- 1
2
3 12. Maclullich, A. M., Ferguson, K. J., Miller, T., de Rooij, S. E., & Cunningham, C.
4
5 Unravelling the pathophysiology of delirium: A focus on the role of aberrant stress
6
7 responses. *Journal of Psychosomatic Research* 2008; 65(3), 229-38.
8
9
- 10 13. Zaal, I. J., Devlin. J. W., Peelen, L. M., Slooter, A. J. A systematic review of risk factors
11
12 for delirium in the ICU. *Crit Care Med* 2015; 43(1):40-7.
13
14 doi:10.1097/CCM.0000000000000625.
15
16
- 17 14. Brummel NE, Jackson JC, Pandharipande PP, Thompson JL, Shintani AK, Dittus RS,
18
19 Gill TM, Bernard GR, Ely EW, Girard TD. Delirium in the ICU and subsequent long-
20
21 term disability among survivors of mechanical ventilation. *Crit Care Med*. 2014
22
23 Feb;42(2):369-77. doi: 10.1097/CCM.0b013e3182a645bd.
24
25
- 26 15. Oke, S. L., & Tracey, K. J. The inflammatory reflex and the role of complementary and
27
28 alternative medical therapies. *Annals of New York Academy of Science* 2009; 1172, 172-
29
30 80.
31
32
- 33 16. Park, E. R., Traeger, L., Vranceanu, A. M., et al. The development of a patient-centered
34
35 program based on the relaxation response: The Relaxation Response Resiliency Program
36
37 (3RP). *Psychosomatics* 2013; 54(2), 165-74.
38
39
- 40 17. Hadjibalassi, M., Lambrinou, E., Papastavrou, E., Papathanassoglou, E. The effect of
41
42 guided imagery on physiological and psychological outcomes of adult ICU patients: A
43
44 systematic literature review and methodological implications. *Australian Critical Care*.
45
46 2017; Mar 29. pii: S1036-7314(17)30164-9. doi: 10.1016/j.aucc.2017.03.001.
47
48
- 49 18. Papathanassoglou E, Hadjibalassi M, Lambrinou E, Papastavrou E, Paikousis L,
50
51 Kyprianou T. Pilot Clinical Trial of the effects of an integrative nursing intervention on
52
53
54
55
56
57
58
59
60

- critically ill patients' pain, hemodynamic measurements, psychological responses and sleep. *American Journal of Critical Care* 2018; 27:172-185.
19. Pan W. Sample size and power calculations with correlated binary data. *Control. Clinical Trials* 2001;22:211–27.
20. Moore CG, Carter RE, Nietert PJ, Stewart PW. Recommendations for planning pilot studies in clinical and translational research. *Clinical Translational Science* 2011; 4(5):332-7
21. Hermann, C. Psychological interventions for chronic pediatric pain: State of the art, current developments and open questions. *Pain Management* 2011; 1(5), 473-83.
22. Dossey, B.M., & Keegan, L. *Holistic Nursing - A Handbook for Practice*. American Holistic Nurses Association. Boston, MA: Jones & Bartlett, 2009.
23. Diego, M. A., & Field, T. Moderate pressure massage elicits a parasympathetic nervous system response. *International Journal of Neuroscience* 2009; 119(5), 630-8.
24. Neto AS, Nassar AP Jr, Cardoso SO, et al. Delirium screening in critically ill patients: a systematic review and meta-analysis. *Crit Care Med* 2012; 40(6):1946-51
25. Robins, J. M., Rotnitzky, A., & Zhao, L. P. Analysis of semiparametric regression models for repeated outcomes in the presence of missing data. *Journal of the American Statistical Association* 1995; 90(429), 106-121.
26. Onwuegbuzie, A. J., Dickinson, W. B., Leech, N. L., & Zoran, A. G. A qualitative framework for collecting and analyzing data in focus group research. *International Journal of Qualitative Methods* 2009; Retrieved from: <http://creativecommons.org/licenses/by/2.0>

- 1
2
3 27. Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009).
4
5 Research Electronic Data Capture (REDCap) - A metadata-driven methodology and
6
7 workflow process for providing translational research informatics support. Journal of
8
9 Biomedical Informatics 2009; 42(2), 377-81.
10
11
12 28. Chan, A-W., Tetzlaff, J.M., Altman, D.G et al. SPIRIT 2013 Statement: Defining Standard
13
14 Protocol Items for Clinical Trials. Annals Internal Medicine 2013;158:200–207.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Contributions: EDEP, YS, KH, JK contributed to study conception, design and manuscript draft. HTS, CN, LR, SB, MM, TP contributed to discussions about design; EDEP, YS, KH, JK, HTS, CN, LR, SB, MM, TP are investigators in the CIHR grant supporting this work. PT contributed to refining data collection strategies. CL and RA contributed to the development and teaching of the massage intervention. TSB contributed to the development of the music therapy piece of the intervention. This study is supported by the Canadian Critical Care Trials group. All authors contributed to refinement of the study protocol and approved the final manuscript.

Funding: This work is supported by a Canadian Institutes of Health Research (CIHR) grant (CIHR PS 148850; PI: EP) and an Alberta Innovates Strategy for Patient Oriented Research (SPOR) Support Grant (PI: EP)

Sponsors's contact data: Canadian Institutes of Health Research, 160 Elgin Street, 9th Floor
Address Locator 4809A, Ottawa ON K1A 0W9, Canada; Tel.: 613-941-2672.

Alberta Innovates- SPOR Support: 1500, 10104 – 103 Avenue, Edmonton, Alberta, T5J 0H8,
Canada; Tel.: 780-423-5727.

Acknowledgements: The authors are grateful to the participating sites: Royal Alexandra Hospital, Edmonton, AB, Canada and University of Alberta Hospital, General Systems ICU, Edmonton, AB, Canada. We wish to thank the Epidemiology Coordinating Research Centre (EPICORE), University of Alberta, for statistics consultation, and Lily Yushko, systems analyst EPICORE for development of patient report forms, and Thilini Herath Mudiyansele for contributions to the final version of the manuscript.

Authors' conflict of interest: None declared

Data Statement: Technical appendix, statistical code, and dataset will be available from EPICORE, University of Alberta.

Legends

Figure 1.

Evidence-based framework for the physiological mechanism implicated in relaxation-induced effects in critical illness. Relaxation acts early at the pathophysiological cascade through which an exaggerated stress response results in pro-inflammatory effects, suppressed PNS outflow and subsequently in systemic inflammation, multiple organ dysfunction and death. The relaxation response counterbalances the exaggerated stress response and activates PNS and cholinergic anti-inflammatory signaling, which downregulates pro-inflammatory (e.g., HMGB-1) and up-regulates anti-inflammatory cytokines; therefore attenuating systemic inflammation and its detrimental organ effects. (*α 7-nAChR: alpha7- nicotinic acetylcholine receptor, HMGB-1: High Mobility Group Box-1; PNS: Parasympathetic Nervous System*)

Figure 2:

Schematic of study design. (*Ach: Acetylcholine, AE: Adverse Event, APACHE: Acute Physiology & Chronic Health Evaluation, CPOT: Critical Care Pain Observation Tool, CRP: C-Reactive Protein, EQ-5D: EuroQol Five Dimensions Questionnaire, HADS: Hospital Anxiety and Depression Scale, HF: High Frequency, HMGB: High Mobility Group Box, HRV: Heart Rate Variability, ICDSC: Intensive Care Delirium Screening Checklist, ICU: Intensive Care Unit, IQCODE: Informant Questionnaire on Cognitive Decline in the Elderly, IV: Intravenous, LF: Low Frequency, LOS : Length of Stay, NRS: Numeric Rating Scale, RASS: Richmond*)

1
2
3 *Agitation Sedation Scale, RGI: Relaxation and Guided Imagery, S-R: Self-Reported, SOFA:*
4
5 *Sequential Organ Failure, STAI: State Trait Anxiety Inventory).*
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

For peer review only

REPOSE 26

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Appendix 1. Schedule of enrolment, interventions, and assessments. Adapted from (28).

	Enrolment	Allocation	Post-allocation in-ICU					Post-intervention / in-ICU (daily until discharge)	At ICU-discharge (or ward-ready)	Post ICU discharge (In hospital: 2-7 days)	At hospital discharge	Post ICU Discharge (6 weeks)	Post ICU Discharge (4 months)
TIMEPOINT	-t ₁	0	Day ₁	Day ₂	Day ₃	Day ₄	Day ₅						
ENROLMENT:													
Eligibility screen	X												
Informed consent	X												
Random Allocation		X											
INTERVENTIONS:													
[Intervention: RGI + massage]			←-----→										
[Control: Sham Intervention]			←-----→										
BASELINE ASSESSMENTS: [demographics diagnosis, hx, short IQCODE), pre-DDRS, sedatives/ analgesics/ antipsychotics dose, Prior LOS]													
	X												
Primary Outcome:		X	X	X	X	X	X						

ICDSC≥4

Secondary outcomes:
ICDSC, ICDSC:1-3, RASS, daily sedatives/analgesics/antipsychotics dose, sleep NRS, sleep duration, APACHE II, SOFA

C-POT, PAIN NRS, pain distress NRS, stress NRS, HF- LF HRV

HMGB-1, CRP, Ach

ICU LOS, duration MV, ICU survival

HADS

Hospital survival, Hospital LOS

6 week survival, Interview, EQ-5D, SF-36


	X	X	X	X	X	X	X						
		pre-post-Intervention											
	X	X2	X2	X2	X2	X2							
		pre-post-Intervention											
		X2	X2	X2	X2	X2							
							X						
								X					
									X				
											X		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

4-month survival, EQ-5D, SF-36																X
---------------------------------------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	---


Ach: Acetylcholine, CPOT: Critical Care Pain Observation Tool, CRP: C-Reactive Protein, DEMMI: de Morton Mobility Index, EQ-5D: EuroQol Five Dimensions Questionnaire,
HADS: Hospital Anxiety and Depression Scale, HF: High Frequency, HMGB: High Mobility Group Box, HRV: Heart Rate Variability, ICDSC: Intensive Care Delirium Screening Checklist, ICU: Intensive Care
Unit, Interview: Qualitative open ended questions; IQCODE: Informant Questionnaire on Cognitive Decline in the Elderly, LF: Low Frequency, LOS : Length of Stay, MV: mechanical ventilation, NRS:
Numeric Rating Scale, RASS: Richmond Agitation Sedation Scale, RGI: Relaxation and Guided Imagery, S-R: Self-Reported, SOFA: Sequential Organ Failure, STAI: State Trait Anxiety Inventory.

For peer review only



190x315mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



778x824mm (96 x 96 DPI)

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	2
Protocol version	#3	Date and version identifier	2
Funding	#4	Sources and types of financial, material, and other support	22
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	22

1	Roles and	#5b	Name and contact information for the trial sponsor	22
2	responsibilities:			
3	sponsor contact			
4	information			
5				
6				
7				
8	22Roles and	#5c	Role of study sponsor and funders, if any, in study	22
9	responsibilities:		design; collection, management, analysis, and	
10	sponsor and funder		interpretation of data; writing of the report; and the	
11			decision to submit the report for publication,	
12			including whether they will have ultimate authority	
13			over any of these activities	
14				
15				
16				
17	Roles and	#5d	Composition, roles, and responsibilities of the	14-15
18	responsibilities:		coordinating centre, steering committee, endpoint	
19	committees		adjudication committee, data management team,	
20			and other individuals or groups overseeing the trial,	
21			if applicable (see Item 21a for data monitoring	
22			committee)	
23				
24				
25				
26				
27	Background and	#6a	Description of research question and justification	4-5
28	rationale		for undertaking the trial, including summary of	
29			relevant studies (published and unpublished)	
30			examining benefits and harms for each intervention	
31				
32				
33				
34	Background and	#6b	Explanation for choice of comparators	5
35	rationale: choice of			
36	comparators			
37				
38				
39	Objectives	#7	Specific objectives or hypotheses	5, 6
40				
41				
42	Trial design	#8	Description of trial design including type of trial (eg,	5
43			parallel group, crossover, factorial, single group),	
44			allocation ratio, and framework (eg, superiority,	
45			equivalence, non-inferiority, exploratory)	
46				
47				
48				
49	Study setting	#9	Description of study settings (eg, community clinic,	6
50			academic hospital) and list of countries where data	
51			will be collected. Reference to where list of study	
52			sites can be obtained	
53				
54				
55	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If	7
56			applicable, eligibility criteria for study centres and	
57				
58				
59				
60				

		individuals who will perform the interventions (eg, surgeons, psychotherapists)	
Interventions: description	#11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	7-8,9
Interventions: modifications	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	8
Interventions: adherence	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	8
Interventions: concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	9
Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	10-12
Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	1. Appendix
Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	6-7
Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size	6

1	Allocation:	#16a	Method of generating the allocation sequence (eg,	8
2	sequence		computer-generated random numbers), and list of	
3	generation		8any factors for stratification. To reduce	
4			predictability of a random sequence, details of any	
5			planned restriction (eg, blocking) should be	
6			provided in a separate document that is	
7			unavailable to those who enrol participants or	
8			assign interventions	
9				
10	Allocation	#16b	Mechanism of implementing the allocation	8
11	concealment		sequence (eg, central telephone; sequentially	
12	mechanism		numbered, opaque, sealed envelopes), describing	
13			any steps to conceal the sequence until	
14			interventions are assigned	
15				
16	Allocation:	#16c	Who will generate the allocation sequence, who	8
17	implementation		will enrol participants, and who will assign	
18			participants to interventions	
19				
20	Blinding (masking)	#17a	Who will be blinded after assignment to	8-9
21			interventions (eg, trial participants, care providers,	
22			outcome assessors, data analysts), and how	
23				
24	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is	9, NA
25	emergency		permissible, and procedure for revealing a	
26	unblinding		participant's allocated intervention during the trial	
27				
28	Data collection plan	#18a	Plans for assessment and collection of outcome,	9-10
29			baseline, and other trial data, including any related	
30			processes to promote data quality (eg, duplicate	
31			measurements, training of assessors) and a	
32			description of study instruments (eg,	
33			questionnaires, laboratory tests) along with their	
34			reliability and validity, if known. Reference to where	
35			data collection forms can be found, if not in the	
36			protocol	
37				
38	Data collection	#18b	Plans to promote participant retention and	9
39	plan: retention		complete follow-up, including list of any outcome	
40			data to be collected for participants who	
41			discontinue or deviate from intervention protocols	
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Data management	#19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	9,15
2				
3				
4				
5				
6				
7				
8				
9				
10				
11	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	13-14
12				
13				
14				
15				
16				
17	Statistics: additional analyses	#20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	13-14
18				
19				
20				
21	Statistics: analysis population and missing data	#20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	14
22				
23				
24				
25				
26				
27				
28	Data monitoring: formal committee	#21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	14-15
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39	Data monitoring: interim analysis	#21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	NA
40				
41				
42				
43				
44				
45				
46	Harms	#22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	16
47				
48				
49				
50				
51				
52				
53	Auditing	#23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	8,15
54				
55				
56				
57				
58				
59				
60				

1	Research ethics	#24	Plans for seeking research ethics committee /	15,16
2	approval		institutional review board (REC / IRB) approval	
3				
4	Protocol	#25	Plans for communicating important protocol	15
5	amendments		modifications (eg, changes to eligibility criteria,	
6			outcomes, analyses) to relevant parties (eg,	
7			investigators, REC / IRBs, trial participants, trial	
8			registries, journals, regulators)	
9				
10				
11				
12				
13	Consent or assent	#26a	Who will obtain informed consent or assent from	15-16
14			potential trial participants or authorised surrogates,	
15			and how (see Item 32)	
16				
17				
18	Consent or assent:	#26b	Additional consent provisions for collection and use	16
19	ancillary studies		of participant data and biological specimens in	
20			ancillary studies, if applicable	
21				
22				
23				
24	Confidentiality	#27	How personal information about potential and	16
25			enrolled participants will be collected, shared, and	
26			maintained in order to protect confidentiality before,	
27			during, and after the trial	
28				
29				
30	Declaration of	#28	Financial and other competing interests for	22
31	interests		principal investigators for the overall trial and each	
32			study site	
33				
34				
35				
36	Data access	#29	Statement of who will have access to the final trial	NA
37			dataset, and disclosure of contractual agreements	
38			that limit such access for investigators	
39				
40				
41	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care,	NA
42	trial care		and for compensation to those who suffer harm	
43			from trial participation	
44				
45				
46	Dissemination	#31a	Plans for investigators and sponsor to	16
47	policy: trial results		communicate trial results to participants,	
48			healthcare professionals, the public, and other	
49			relevant groups (eg, via publication, reporting in	
50			results databases, or other data sharing	
51			arrangements), including any publication	
52			restrictions	
53				
54				
55				
56				
57				
58				
59				
60				

1	Dissemination	#31b	Authorship eligibility guidelines and any intended	NA
2	policy: authorship		use of professional writers	
3				
4	Dissemination	#31c	Plans, if any, for granting public access to the full	16
5	policy: reproducible		protocol, participant-level dataset, and statistical	
6	research		code	
7				
8	Informed consent	#32	Model consent form and other related	Upon request
9	materials		documentation given to participants and authorised	
10			surrogates	
11				
12	Biological	#33	Plans for collection, laboratory evaluation, and	12-13 & upon
13	specimens		storage of biological specimens for genetic or	request
14			molecular analysis in the current trial and for future	
15			use in ancillary studies, if applicable	
16				
17				
18				
19				
20				
21				

22 The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-
 23 BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made
 24 by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

BMJ Open

Relaxation for Critically ill Patient Outcomes and Stress-coping Enhancement (REPOSE): A protocol for a pilot randomized trial of an integrative intervention to improve critically ill patients' delirium and related outcomes

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023961.R1
Article Type:	Protocol
Date Submitted by the Author:	03-Aug-2018
Complete List of Authors:	Papathanassoglou, Elizabeth; University of Alberta, Faculty of Nursing Skrobik, Yoanna; McGill University, Medicine Hegadoren, Kathleen; University of Alberta, Faculty of Nursing Thompson, Patrica; 3. Royal Alexandra Hospital, Edmonton, AB, Canada, Critical Care Medicine Stelfox, Henry; University of Calgary, Critical Care Medicine Norris, Colleen; University of Alberta, Faculty of Nursing Rose, Louise; University of Toronto, Lawrence S. Bloomberg Faculty of Nursing Bagshaw, Sean; University of Alberta, Critical Care Medicine, Faculty of Medicine & Dentistry Meier, Michael; University of Alberta, Critical Care Medicine, Faculty of Medicine & Dentistry LoCicero, Cheryl Ashmore, Rhonda Sparrow Brulotte, Tiffany ; University of Alberta Hassan, Imran; University of Alberta, EPICORE Park, Tanya; University of Alberta, Faculty of Nursing Kutsogiannis, Demetrios J; University of Alberta, 2. Department of Critical Care Medicine, Faculty of Medicine and Dentistry
Primary Subject Heading:	Intensive care
Secondary Subject Heading:	Complementary medicine, Nursing
Keywords:	critical illness, music therapy, relaxation, guided imagery, delirium, complex intervention

SCHOLARONE™
Manuscripts

Relaxation for Critically ill Patient Outcomes and Stress-coping Enhancement (REPOSE):

A protocol for a pilot randomized trial of an integrative intervention to improve critically ill patients' delirium and related outcomes

Elizabeth D.E. Papathanassoglou, RN, PhD^{1*}, Yoanna Skrobik, MD FRCP(c) MSc FCCP⁴, Kathleen Hegadoren, RN, PhD¹, Patrica Thompson, RN, CCRP³, Henry T. Stelfox, MD, PhD⁵, Colleen Norris, RN, PhD¹, Louise Rose, RN, PhD^{6,7}, Sean Bagshaw, MD, PhD^{2,8}, Michael Meier, MD, PhD^{2,8}, Cheryl LoCicero, BSc⁹, Rhonda Ashmore, MScPT¹⁰, Tiffany Sparrow Brulotte, MTA¹¹, Imran Hassan, MSc¹², Tanya Park, RN, PhD¹, Demetrios J. Kutsogiannis MD MHS FRCPC^{2,3}

1. University of Alberta, Faculty of Nursing, Edmonton, AB, Canada
2. Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
3. Royal Alexandra Hospital, Edmonton, AB, Canada
4. Department of Medicine, McGill University; Regroupement de Soins Critiques Respiratoires, FRQS
5. Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
6. Sunnybrook Health Sciences Centre, Toronto, ON, Canada
7. King's College London, London, UK
8. University of Alberta Hospital, General Systems ICU, Edmonton, AB, Canada
9. Registered Massage Therapist (RMT), Certified Advanced Rolfer
10. Registered Massage Therapist (RMT), PT
11. Accredited music therapist (BMT, MTA), MA candidate in ethnomusicology
12. Biostatistician, EPICORE Centre, University of Alberta

(*): To whom correspondence should be addressed.

Key words: critical illness, music therapy, relaxation, guided imagery, autonomic nervous system, delirium, complex intervention

Word count: 4,695

Correspondence: Elizabeth D. E. Papathanassoglou, University of Alberta, Faculty of Nursing, 5-262 Edmonton Clinic Health Academy (ECHA), 11405-87th Ave. Edmonton, Alberta, Canada T6G 1C9, Tel.: (780) 492-5674 (w), (780) 237-9375 (c), e-mail: papathan@ualberta.ca

Abstract

Introduction: Delirium is a common complication of critical illness, associated with negative patient outcomes. Preventive or therapeutic interventions are mostly ineffective. Although relaxation-inducing approaches may benefit critically ill patients, no well-designed studies target delirium prevention as a primary outcome. The objective of this study is to assess feasibility and treatment effect estimates of a multimodal integrative intervention incorporating relaxation, guided imagery, and moderate pressure touch-massage for prevention of critical illness delirium and for related outcomes.

Methods and analysis: Randomized, controlled, single-blinded trial with 2 parallel groups (1:1 allocation: intervention and standard care) and stratified randomization [age (18-64, ≥ 65), presence of trauma) with blocking, involving 104 patients with Intensive Care Delirium Screening Checklist (ICDSC): 0-3 recruited from 2 academic ICUs. Intervention group participants receive the intervention in addition to standard care for up to 5 consecutive days (or until transfer/ discharge); control group participants receive standard care and a sham intervention. We will assess pre-defined feasibility outcomes, i.e., recruitment rates, protocol adherence. The primary clinical outcome is incidence of delirium (ICDSC ≥ 4). Secondary outcomes include pain scores, inflammatory biomarkers, heart rate variability, stress and quality of life (6 weeks; 4 months) post-ICU discharge. Feasibility measures will be analyzed descriptively, and outcomes longitudinally. Estimates of effects will be calculated.

Ethics and dissemination: The study has received approval from the Human Research Ethics Board, University of Alberta. Results will inform the design of a future multi-center trial.

Registration: clinicaltrials.gov (NCT02905812).

Protocol date: March 3, 2018, version 5, Protocol amendment number: 07

Primary reasons for amendment: Refining feasibility of intervention and data collection.

Summary

Strengths and limitations of this study

- We will test feasibility and measures of effect of a previously piloted relaxation-inducing intervention for the prevention of delirium and improvement of related outcomes in critically ill patients.
- We will employ an evidence-based, non-pharmacological multimodal integrative intervention that has shown effectiveness for reducing pain and improving a number of secondary outcomes in a previous pilot study.
- This pilot aims to assess estimates of effect and feasibility to inform a future trial.
- Although clinicians and outcome assessors will be blinded, due to the nature of the intervention, participants and nurses providing direct care to patients cannot be blinded to allocation, although they will be blinded to the study hypotheses.
- The mechanisms of effects of relaxation-inducing interventions in critical illness are not well understood; hence, we aim to explore effects of the intervention on parasympathetic system activation and inflammatory markers.

Introduction

ICU delirium affects 35-55% of critically ill patients, and is independently associated with a 13-fold (adjusted odds ratio (OR):4.88-13.0) increased risk of death (1) and long-term cognitive impairment (2). ICU delirium carries important financial and societal burdens [(39% higher adjusted ICU (95% CI:12-72%), and 31% higher hospital costs (95% CI:1-70%)] (3). Moreover, patients identify frightening delirium experiences and pain as the most severe stressors (4,5) in critical care. Pharmacological interventions for the prevention and treatment of delirium have limited benefit and are associated with high costs and risks for side effects (6,7). Although clinical guidelines recommend the development of non-pharmacological interventions to prevent delirium (8), effective prevention strategies have yet to be established (9).

A prolonged and eventually aberrant stress response and depressed parasympathetic (PNS) activity have been postulated as the pathophysiological basis for the development of both ICU delirium and systemic inflammation (10-13). Frightening hallucinations and ideations during delirium may further exaggerate the stress-response and prolong critical illness with detrimental consequences. Pain may worsen matters by reciprocal incremental feed-back on inflammation and stress (4, 14). Thus, in critical illness, stress, delirium, pain and systemic inflammation may comprise a self-perpetuating syndrome. Attenuating the cascade of negative health impacts from pain and delirium has become a high clinical priority (Figure 1) (8). Moreover, the growing recognition that delirium and other critical illness sequelae may have long term consequences in critical illness survivors (15) further highlights the need for prevention strategies.

Evidence-based theoretical work postulates that the multitude of psychological stressors in critically ill individuals may contribute to the development of pathophysiologic sequelae (10).

Moreover, animal models illustrate that PNS stimulation and acetylcholine (ACh) release suppress inflammation and decrease fatality, via the cholinergic anti-inflammatory pathway (16). Devising ways to draw on the autonomic nervous systems' inflammation- and stress-regulatory properties by non-pharmacological interventions has, in theory, the potential to improve outcomes with low side-effect risk. However, stimulation of the PNS in critical care is challenging. Relaxation-inducing interventions can induce PNS activity. Such approaches have successfully been used in diverse patient populations to counter stress, but remain under-tested in critical illness (17). A recent systematic review shows favorable effects of relaxation and guided imagery intervention in reducing pain, anxiety and length of stay in critically ill patients (18); whereas, the relaxation inducing effects of music in critical care have been well supported by evidence (19). In a pilot randomized controlled trial (RCT) of the effects of a similar multimodal intervention on the incidence of pain and on a number of secondary outcomes, we observed significant decreases in pain incidence (RR=0.56, p=0.003) and severity (p<0.0001), systolic arterial pressure, anxiety, along with improved sleep quality (20).

Hypotheses

Overall, we hypothesize that a multimodal intervention incorporating relaxation and guided imagery (RGI) and moderate pressure touch-massage is feasible within a critical care setting, and can have an effect on decreasing delirium and in improving physiological and psychological outcomes in randomized critically patients who will receive standard care and the intervention compared to patients receiving standard care plus a sham intervention only.

Primary Hypotheses:

We hypothesize that the intervention will be feasible and that it will have an effect on decreasing delirium incidence and duration.

Secondary hypotheses:

We hypothesize that the intervention will have an effect on: a) incidence rate of subsyndromal delirium, time to delirium occurrence, proportion of delirium-free time during up to 8 days of ICU stay; b) sedation levels and daily sedative, analgesic and antipsychotic agent dose; c) pain occurrence and intensity; d) perceived stress level; e) sleep duration and quality; f) anxiety; g) length of ICU stay and duration of mechanical ventilation/ proportion of mechanical ventilation-free days; h) hospital LOS, i) physiological biomarkers; and k) quality of life after ICU discharge.

Design and Methods

Study design

Relaxation for Critically ill Patient Outcomes and Stress-coping Enhancement (REPOSE) is a pilot feasibility, randomized, controlled, single-blinded trial with 2 parallel groups (intervention and standard care). Accounting for major risk factors of delirium (15), stratified randomization according to age (18-64, ≥ 65) and presence of either surgical or trauma injury with blocking and 1:1 allocation to assure balance in numbers per group will be employed.

Research Objectives

Research objectives include to:

a) Assess clinical trial feasibility with pre-defined goals (enrolment, randomization, adherence, timing of intervention, workload)

- 1
2
3 b) Calculate estimates and variance of treatment effect across outcome measures
4
5
6 c) Calculate Confidence Intervals (CI) of incidence proportions, means and Standard Deviation
7
8 (SD) of outcome measures in study groups, and
9
10
11 d) Explore the feasibility of identifying underlying physiological mechanisms
12
13

14 *Setting, recruitment and sample size*

15
16
17 Consecutive patients admitted to 2 academic ICUs, in Edmonton, AB, Canada, with an ICDSC
18 score of 0-3 will be screened for study eligibility and will be recruited by research staff at each
19 site. In cases where an ICDSC score cannot be obtained on admission, we will screen patients for
20 up to 4 days after admission. Since delirium occurs most often within the first 5 days of
21 admission, screening and enrolment will take place as soon as possible and within 96 hours after
22 ICU admission. This pilot is not powered to determine a difference in a primary outcome, since
23 we aim to assess estimates of effect. For a definitive trial, we would require 290 (145/arm)
24 patients to detect a 10% difference in incidence proportion between intervention (20%) and
25 control (30%) arm (two-sided $\alpha=0.05$, power=80%, drop-out rate=10%). The Pan method
26 (21), which is based on generalized estimating equations, was used to perform the sample size
27 calculation under the assumption of AR(1) correlation structure among 5 days repeated
28 measurements with correlation between any two adjacent observations from the same subject of
29 0.5. Since this is a pilot, aiming to explore feasibility and estimates of effects, and the incidence
30 rates used for the calculation might not be appropriate, we used 36% of the sample size of the
31 full study to estimate the parameters accurately and get an experience for a full trial (22).
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 *Eligibility*

52
53
54
55 Inclusion criteria: a) Age over 18 years, b) ICDSC:0-3, c) written informed consent.
56
57
58
59
60

1
2
3 Exclusion Criteria: Patients: a) Already in the ICU for more than 96 hours, b) with ICDSC>3
4 within 72 h of screening in case intervention has not been initiated, c) on special contact
5 precautions (i.e., MRSA, VRE, HIV), d) with expected Intensive Care Unit (ICU) Length of stay
6 (LOS) < 72 hours, e) with acute neurological illness/ neurological trauma, persistent deep
7 sedation or coma [Richmond Agitation Sedation Scale (RASS = -4, -5)] f) with current history of
8 severe mental health problems and dementia, as per history, g) with hearing impairment or
9 conditions not permitting use of headphones, h) on neuro-muscular blockers, i) with known or
10 suspected substance/ alcohol withdrawal, and j) enrolled in trials of sedatives, antipsychotics.

21 *Patient and Public involvement*

22
23
24 The protocol is based on a pilot study with 60 randomized patients (20), 12 of which provided
25 feedback regarding the desirability, burden and specific components of the intervention, study
26 procedures and preferred outcomes. Participants' feedback informed the design of the study,
27 resulting in many significant changes. Preferred post-ICU follow-up times were informed by an
28 informal advisory group through the Alberta Innovates Strategy for Patient Oriented Research
29 (SPOR) network of patient representatives. Moreover, as a patient and clinician engagement
30 strategy, an advisory group with representatives of patients, families and clinicians will act as a
31 consultation group for the research team. Acceptance and desirability will be assessed further.

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Recommendations will inform future development of the intervention and research design.

Canadian Institutes of Health Research (CIHR) guidelines for patient engagement will be used to
establish and facilitate the advisory group. Feedback on: a) concerns on the intervention, study
processes, contamination of the control group by implementation of aspects of the intervention,
b) desirability of intervention (massage, music choices, complexity, voice of recording, pace), c)
timing within the day, d) duration/ feasibility of the intervention, e) burden of study processes, f)

1
2
3 outcomes to be addressed in the future trial, g) interpretation of results, h) strategies for
4
5 dissemination of findings will be collected.
6
7

8 **Intervention**

9
10
11 The choice of a multimodal intervention (duration: 55min) was based on an evidence-based
12
13 literature review, its superiority to unidimensional approaches (23), the recommendations of the
14
15 American Holistic Nurses Association (24) and a successful pilot (20). According to the UK
16
17 Medical Research Council (MRC) guidance for complex intervention trials (25), development of
18
19 the protocol included extensive theoretical work (10), two systematic reviews (18, 26), modeling
20
21 of outcomes, extensive consultations with groups of experts, one small feasibility and
22
23 acceptability pilot (n=10 participants) and one larger pilot (n=60) (20) and consultation with pilot
24
25 participants and patients' representatives. The intervention has been developed by the research
26
27 team and a group of experts based at the University of Alberta and Cyprus University of
28
29 Technology. It includes: a) a brief moderate pressure massage session (massage: 15 minutes), b)
30
31 relaxation and guided imagery (30 minutes, through headphones). The 30 min recorded RGI
32
33 intervention involves: a) guided relaxation, b) a structured guided imagery script supported by
34
35 instrumental music, and c) recorded instrumental music for 15 minutes (Haydn concerto no 1 in
36
37 C major and Bach violin concerto in D minor, 60 beats per min approximately). The same
38
39 recorded RGI script will be used at all sessions. It includes positive suggestions and instructions
40
41 for gradual relaxation, followed by guidance to visualize one's body being healed. Moderate
42
43 pressure (4 N, approximately or patient pressure rating 3/10) low velocity (1-5cm/second)
44
45 massage consists of broad and repetitive circular movements with wide area of contact, applied
46
47 sequentially for 2-3 minutes at each site: hands, forearms, lateral arms, and then over trapezius
48
49 muscles, the temple, scalp, face and forehead area. Areas are to be contacted as appropriate to
50
51
52
53
54
55
56
57
58
59
60

REPOSE 9

1
2
3 each participant, and the protocol may be adapted taking into account safety issues (i.e., to avoid
4 area around intravascular catheter or injury). Moderate pressure massage is involved in PNS
5 activation, in contrast to light pressure (27). The intervention will be administered once daily
6
7 (09:00-15:00) for up to 5 consecutive days by trained research staff not involved in patient care,
8
9 who will be randomly audited by the Trial Steering Committee (TSC) to ensure protocol
10 adherence. The decision to deliver the intervention for the first 5 days after enrollment only was
11 based on epidemiological data regarding the onset of delirium (9), data on median length of stay
12 of the target populations in the study institutions and cost considerations. However, it will be
13 important to study the effect of the intervention on longer stay patients in future trials. The
14 decision to deliver only one intervention daily was based on a small acceptability/ feasibility
15 pilot, and pragmatic considerations for knowledge translation and future implementation of this
16 approach, as well as cost considerations and burden to participants and units. The durations of
17 guided imagery, music therapy and touch intervention were based on the acceptability pilot,
18 expert opinions on the minimum duration to achieve a relaxation effect and on published
19 evidence (18). Despite evidence on the importance of providing choice to patients regarding
20 music therapy (19), we will use standardized music for intervention stability purposes. It will be
21 important to look at the effect of patient-directed music in future trials of this intervention.
22
23 Interruptions and deviations from the intervention protocol will be recorded in detail. The
24 intervention will be terminated upon a patient's transfer or discharge from the ICU. The
25 intervention may be discontinued in case of adverse events related to the intervention or
26 withdrawal of consent. If we observe ICDSC scores above 3 once the intervention has been
27 commenced, the intervention will be continued, unless otherwise indicated by a participant's
28 condition. Although, contamination of the control group by spontaneously mimicking aspects of
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the intervention by health care personnel cannot be excluded, health care providers in the units
4 are very familiar with clinical trials and have been instructed on the need to abstain from
5
6 mimicking the intervention. Additionally, the touch component of the intervention requires
7
8 specific training and it is unlikely to be successfully replicated.
9
10

11 12 13 *Randomization and allocation concealment*

14
15
16 Participants will be randomly assigned to either control or intervention group (1:1 allocation) as
17
18 per a computer-generated randomization schedule, generated by the Epidemiology Coordinating
19
20 Research Centre (EPICORE), University of Alberta (UofA), stratified by site, age (18-64, ≥ 65),
21
22 and presence of surgery or trauma using permuted blocks of random sizes. The block size will
23
24 not be disclosed to ensure concealment. After baseline measurements, allocation will be
25
26 disclosed only to the intervention staff. Codes will be generated prior to the beginning of the
27
28 study by EPICORE.
29
30

31 32 33 *Blinding*

34
35
36 Investigators, physicians and nurses (when possible), data collectors, research assistants, and
37
38 laboratory technicians will be blinded to group allocation during the trial and analysis. Due to the
39
40 nature of the intervention, participants cannot be blinded to allocation. Also, participants'
41
42 primary nurses cannot be blinded to study procedures (i.e., delivery of massage); however, they
43
44 will remain blinded to study hypotheses, study design (i.e., study outcomes, numbers and types
45
46 of participants' groups) and allocation. We believe that these procedures along with the sham
47
48 intervention will maintain an adequate level of concealment even among participants' primary
49
50 nurses, to minimize bias. The same intervention personnel will be involved in the delivery of the
51
52 intervention and sham intervention. Intervention personnel are not involved in assessment of
53
54
55
56
57
58
59
60

1
2
3 patient outcomes, and have been trained on the importance of preserving blinding, therefore
4
5 minimizing the risk for potential bias.
6
7

8 *Treatment arms*

9

10
11 Patients randomly allocated to the intervention group will receive the intervention in addition to
12
13 standard care (standard care + multimodal intervention group). Patients allocated to the control
14
15 group will receive standard care and a sham intervention consisting of presence of a research
16
17 staff at the bedside with drawn curtains and silent headphones (standard care + sham intervention
18
19 group; Schematic of study design in Figure 2).
20
21

22 *Concomitant care*

23

24
25 Standard care will be continued for all participants. Type and dose of all administered sedative,
26
27 psychoactive and analgesic medication will be recorded.
28
29

30 *Duration of participation*

31

32
33 The total duration may vary according to ICU length of stay and will be 17 weeks
34
35 approximately, from enrolment until the last follow up at 4 months post-ICU discharge.
36
37

38 **Data Collection and Instruments**

39

40
41 Data will be collected for each participant by blinded data collectors and captured in a Research
42
43 Electronic Data Capture (RedCap®) database developed and monitored by EPICORE. Time
44
45 points include: baseline measurements, follow-up while in the ICU for up to 5 days, follow up
46
47 48-96 hours after ICU discharge, follow-up 6 weeks and 4 months after ICU discharge. In case
48
49 of participants who discontinue participation, data already collected will be retained.
50
51
52
53
54
55
56
57
58
59
60

All study scales are routinely used in clinical practice and have established psychometric properties. The ICDSC is one of the most reliable tools for assessment of ICU delirium advocated by recent guidelines (4, 28). Inter-observer reliability of and sensitivity (80.1, 95% CI:73.3-85.8) of ICDSC have been established and will be further assessed in this study (28). For comatose, deeply sedated patients [Richmond Agitation Sedation Scale (RASS = -4, -5)] delirium cannot be assessed. Data captured on Case Reports Forms are included in Figure 2. Baseline data captured at enrolment will include: Sociodemographic data, admission diagnosis, history of alcohol use, medications prior to admission, metabolic acidosis, ICDSC, RASS, Short Form Informant Questionnaire on Cognitive Decline in the Elderly (Short IQCODE), Pre-Deliric Delirium Risk Score, baseline IV sedation, analgesia and antipsychotic dose, disease severity at admission (Acute Physiology & Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment: SOFA), number of days in hospital and ICU prior to protocol enrolment. For pain, scores obtained at the first pre-intervention measurement will be considered as baseline.

Outcome Measures

Primary and secondary outcome, as well as feasibility, measures include (Appendix 1):

- A. Primary clinical outcome:** a) Incidence rate of delirium (ICDSC ≥ 4), during 5 days of intervention (first 5 days of enrolment). Presence of delirium will be assessed by blinded trained nurse assessors 2 times daily (8am, 8pm).
- B. Secondary outcomes [Estimates, variance of effects, proportions and means, SD (where applicable) per group]:**
 - 1. Delirium related secondary outcomes:** a) Incidence rate of delirium (ICDSC ≥ 4) during ICU stay and post-intervention, b) incidence rate of subsyndromal delirium (ICDSC: 1-

- 1
2
3 3) during the intervention period and subsequent ICU stay, c) time to delirium
4
5 occurrence, d) proportion of delirium-free time during up to 8 days of ICU stay
6
7 (excluding periods with deep sedation, coma), e) Sedation levels (Richmond Agitation
8
9 Sedation Scale (RASS) score, f) Daily sedative (benzo-equivalents and propofol),
10
11 analgesic (morphine equivalents) and antipsychotic agent (type, mg/24 hours) dose.
12
13
- 14 2. Pain related outcomes (Pre- and post-intervention): a) Pain intensity (self-reported (S-R)
15
16 numeric rating scale (NRS) for patients able to self-report, pain indicators (Critical Care
17
18 Pain Observation Tool (CPOT) in patients unable to self-report, b) perceived stress level
19
20 (S-R NRS).
21
22
- 23 3. Sleep (Daily): a) Sleep quality (S-R NRS), b) sleep duration (in minutes) (sleep monitors
24
25 and nurses' log). Although more reliable, due to considerations around burden to the unit
26
27 and cost, we do not use polysomnography in this pilot.
28
29
- 30 4. Disease severity (Daily): Sequential Organ Failure (SOFA) score
31
32
- 33 5. Physiological Biomarkers (Pre- & post-intervention): a) Serum Inflammation
34
35 biomarkers [High-mobility-group-box 1 (HMGB-1), C-reactive protein (CRP) levels, b)
36
37 High (HF) and low frequency (LF) components of heart rate variability (HRV) as
38
39 measures of PNS status, c) Serum ACh levels, as a measure of PNS activation. The
40
41 choice of biomarkers was based on the theoretical framework guiding this work
42
43 (triggering of a relaxation parasympathetic response and attenuation of the inflammatory
44
45 response; Figure 1), and results of the pilot study (20, 29), which showed alterations in
46
47 biomarkers immediately post-intervention and over-time, despite great variability in
48
49 biomarker levels. The results will help us generate more informed hypotheses for a
50
51 subsequent trial.
52
53
54
55
56
57
58
59
60

6. Psychological outcomes (2-7 day after ICU discharge): Anxiety (Hospital Anxiety and Depression Scale: HADS & State Trait Anxiety Inventory-6: STAI-6)
7. Clinical outcomes (At discharge): a) length of ICU stay (ICU LOS) (or ward-ready), b) Duration of mechanical ventilation/ proportion of mechanical ventilation-free days, c) survival, d) hospital LOS and e) (3 months post-ICU discharge): 90-day survival.
8. Quality of life outcomes (6 weeks and 4 months post-ICU discharge): EuroQol Five Dimensions Questionnaire (EQ-5DL), Short Form 36 Health Survey (SF-36)
9. Recollection and perception of the intervention (2-7 days after ICU discharge and 6 weeks post-ICU discharge): Qualitative open-ended questions to explore recollection of intervention, views on intervention and acceptability (**Appendix 2**).

C. Feasibility

1. Acceptability: Number of patients refusing or wishing to discontinue a session.
Acceptability will be further assessed with the patients and clinicians advisory group.
2. Enrolment & consent: a) percentage (%) of eligible patients; reasons for non-eligibility, b) time from admission to enrolment, c) recruitment rates, d) % of patients declining consent
3. Randomization & concealment: a) time from enrolment to randomization, b) % of cases at which allocation was inappropriately revealed; description of incident.
4. Protocol adherence & intervention fidelity: Percentage of: a) participants completing the entire study protocol, b) sessions missed, interrupted, delayed; reasons. Adherence to intervention protocol assessed by random observation audits.

- 1
2
3 5. *Data Collection & management:* a) timeliness, accuracy of data collection, reliability,
4 b) testing of trial database, c) type, % of missing values, d) qualitative data on
5 participants' perceptions of the study, e) time required for all study procedures and
6 intervention (to be used in future economic assessment and assessment of burden of
7 the trial).
8
9
10
11
12
13

14 *Primary Feasibility criteria:*

15 The study design will be considered feasible if the following 5 criteria are met:
16

- 17
18
19 a) Eligible patients declining consent < 60%
20
21 b) Cases at which allocation was inappropriately revealed < 3%
22
23 c) Participants withdrawing from study protocol while still in the ICU < 10%
24
25 d) Average sessions missed per patient < 40%
26
27 e) Average sessions interrupted per patient < 50%
28
29
30
31
32
33

34 **Biomarker quantifications**

35
36 *Blood sampling*

37
38
39 One 5 ml blood sample will be collected in pre-coded general anti-coagulated vials, through an
40 intravascular catheter already in place, within 10 min before and 10 min after the intervention.
41
42
43
44

45 *Biomarker analyses*

46
47
48 a. *Serum levels of HMGB-1, ACh and CRP.*

49
50
51 These will be quantified by commercially available sandwich enzyme-linked immunosorbent
52 colorimetric assay (ELISA) kits (LifeSpan Biosciences, Seattle; WA, Biosource, S. Diego, CA;
53 R & D Systems, Minneapolis, MN, respectively). Intra- and inter-assay coefficients of variation
54
55
56
57

(CV) are expected to be less than 10%. All samples will be tested within the same assay run in duplicate by a specialized laboratory technician. Measurements will be carried out at the Women's Health Research Laboratory, Faculty of Nursing, University of Alberta.

b. ANS (Autonomic Nervous System) activity: HF, LF AND LF/HF ratio

ANS activity will be assessed through frequency domain analysis of electrocardiographic (ECG) recordings. ECG recordings will be logged using the Zephyr™ BioModule™ and data will be imported into the OmniSense™ software. Data from OmniSense™ will then be uploaded to Kubios HRV software (Kubios HRV- Heart Rate Variability Analysis Software) and HF, LF and LF/HF ratios will be computed. HRV data will be analyzed for 5 minutes before the intervention, 5 minutes after the intervention and several times during the intervention based on the timing of its various components. Specifically, HRV components will be analyzed on the 8th and 15th minute of massage (half-way and conclusion of massage), 3rd and 15th minute of RGI (induction and conclusion of RGI), and end of music therapy.

Data Analysis

Statistical Methods

Demographic/ clinical characteristics of patients and all outcomes will be presented by treatment group using descriptive statistics— mean (SD), median (IQR) or proportion. Outcomes will be analyzed longitudinally over 5 days by logistic regression model based on generalized estimating equations (GEE) with AR(1) correlation structure. ANCOVA, t-test or Mann-Whitney test, as appropriate, will be conducted for the continuous outcomes that are not longitudinal. Models will be adjusted for co-variables including pre-deliric score, administration of medication (sedatives, analgesics, vasoactives and antipsychotics) and severity score (SOFA, APACHE). Chi-square or

1
2
3 exact test, as appropriate, will be used for categorical outcomes. We will treat pain outcomes as
4 both categorical (presence or absence of pain) and continuous variables (pain score). Confidence
5 intervals will be presented with estimated effects. Primary analysis will be based on all available
6 data utilizing data from all assessments. Since GEE assumes missing completely at random
7 (MCAR) mechanism, we plan to conduct a sensitivity analysis based on inverse probability
8 weighted GEE (IPWGEE) (30) which employs a less restrictive missing at random (MAR)
9 mechanism. A “last observation carried forward” (LOCF) approach was not considered because
10 analyzing all available data performs better than LOCF in GEE setting with respect to bias, Type
11 I error rate and coverage probability under both MCAR and MAR mechanisms. Analysis will be
12 conducted by EPICORE.
13
14
15
16
17
18
19
20
21
22
23
24
25

26
27 To account for noncompliance, protocol deviations and missing outcomes, intention-to-treat
28 (ITT) analysis will be employed. ITT analysis includes every randomized subject according to
29 treatment assignment. Additionally, per protocol analysis will also be employed. Per-protocol
30 (PP) population is defined as a subset of the ITT population who completed the study without
31 any major protocol violations. If ITT and PP analyses lead to similar conclusions the reliability
32 of results will be supported. Although, this is a pilot trial, ITT will help reduce potential effects
33 of selection bias. PP analysis will assess whether the ITT result is too conservative. This will
34 provide important data regarding the effect size for the subsequent trial. Both analyses will assist
35 us in revising the protocol for the larger trial.
36
37
38
39
40
41
42
43
44
45
46
47

48 *Qualitative analyses*

49

50
51 Interview transcriptions will be thematically analyzed by an inductive content analysis approach
52 (31). A coding scheme will be developed based on recurrent themes of the first five interviews.
53
54 Subsequently, two researchers (EP, TP) will code independently, using axial and inductive
55
56
57

1
2
3 coding to formulate a final coding template by consensus. The final coding scheme will then be
4
5 used to code, compare and interpret all transcripts. Individual analyses of the team members will
6
7 be discussed to achieve shared understanding and to increase reliability. The data will be
8
9 analyzed via NVivo software (QSR International Doncaster, Victoria, Australia).

12 13 **Quality Control and Quality Assurance**

14
15
16 This pilot will be supervised by an independent trial steering committee (TSC), consisting of 3
17
18 clinical trial experts independent of the research team. Periodical audits of the intervention and
19
20 trial processes at both sites by personnel independent from investigators will be initiated by the
21
22 TSC. Randomization, recruitment, intervention adherence, blinding, stability and data collection
23
24 processes will be monitored. Trial Monitoring Committee (TMC) will also review relevant
25
26 information from similar studies and will consider the recommendations of the Data Monitoring
27
28 (DMC) and Ethics Committee. Study personnel have been trained to standardize processes. We
29
30 have developed two training videos including detailed demonstration of the intervention.
31
32 Moreover, research personnel involved with the intervention has received 18-21 hours of hands-
33
34 on training, including detailed auditing, and several hours of self-paced training to standardize
35
36 the process, communication and timing of intervention. Study personnel will meticulously record
37
38 any deviations from the intervention protocol to assess feasibility and effect on outcomes.
39
40 Clinical data will be retrieved from the quality-controlled clinical information system of the
41
42 units. Detailed electronic data collection forms with embedded quality controls will be used and
43
44 reviewed in detail. Data quality will be monitored through EPICORE before, during, and after
45
46 entry. All data will be entered electronically using study forms generated through RedCap® with
47
48 embedded quality control processes. Study data will be collected and managed using REDCap®
49
50 electronic data capture tools hosted at the University of Alberta (32). A quality control system
51
52
53
54
55
56
57
58
59
60

REPOSE 19

1
2
3 will be applied for biological measurements as per lab protocol. Day-to-day operations of the
4 trial will be overseen by a Trial Management Group (TMG) comprising, as a minimum, the
5 Principal Investigator, Senior Trial Manager, Trial Manager, Trial Statistician and Data
6 Manager. TMG meetings will take place on a regular basis throughout the duration of the study.
7
8 The TMG will have responsibility for ensuring the adherence and progress of the study in
9 relation to all regulatory, administrative academic and any clinical or safety issues.
10
11
12
13
14
15
16

17 **Ethics**

18
19
20 The protocol has received approval from the Human Research Ethics Board (HREB) University
21 of Alberta and administrative approvals from participating institutions. This study will be
22 conducted in compliance Canadian and International Good Clinical Practice standards. No
23 deviation from the protocol will be implemented without the prior review and approval of the
24 HREB except where it may be necessary to eliminate an immediate hazard to a research
25 participant. In such case, the deviation will be reported to the HREB.
26
27
28
29
30
31
32
33
34

35 Experienced research personnel not involved with the delivery of the intervention and in
36 patient care will acquire informed consent from legal surrogates or participants if competent to
37 consent. Participant assent will be acquired when participants regain capacity. Confidentiality,
38 anonymity and right to withdraw at any point with no questions asked and no effect on the
39 quality of care received will be assured. After completion of the study the data and samples will
40 remain stored at the academic institution for 5 years.
41
42
43
44
45
46
47
48

49 *Confidentiality*

50
51
52 Code-identified encrypted study data will be stored separately from participant information at an
53 EPICORE database permitting code-access only. All study forms, lab specimens and data will be
54
55
56
57

1
2
3 identified by an alphanumeric code to maintain confidentiality. Records that contain names,
4
5 identifiers will be stored separately from study data identified by code. Participants' information
6
7 will not be released outside the study. Participant information will be stored at an encrypted
8
9 limited code-initiated access electronic file. Consent forms will be kept in a locked file cabinet at
10
11 a pre-specified limited-access room, University of Alberta.
12
13
14
15

16 **Safety**

17
18
19 Although prior pilot data did not provide evidence of adverse effects or increased rate of
20
21 complications, any physiological/ behavioural alteration during interventions will be recorded
22
23 and analysed. Adverse events, irrespective of causal relationship, will be collected for all
24
25 participants, during and up to half an hour after the intervention.
26
27
28

29 **Data Dissemination**

30
31
32 Results will be disseminated to participants, healthcare professionals, health services authorities
33
34 and the public via conference presentations and publications. Results of this study will be used to
35
36 inform the design and conduct of a future multi-center trial. The results of the trial will be
37
38 presented at national and international meetings and published in peer-reviewed journals. A lay
39
40 summary of the results will be available to trial participants on request. An online summary of
41
42 the findings will also be made available.
43
44
45
46

47 **Conclusions:** This pilot clinical trial integrates a low-risk, patient-centered strategy, translational
48
49 research and psychological outcomes to allow an evaluation of non-pharmacological delirium
50
51 management with mechanistic insights. Implications of the definitive trial include the potential to
52
53
54
55
56
57

1
2
3 reassure patients, decrease the incidence of frightening delirium experiences, and improve
4
5 longitudinal outcomes.
6
7
8
9

10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

1. Zaal IJ, Slooter AJ. Delirium in critically ill patients: epidemiology, pathophysiology, diagnosis and management. *Drugs* 2012; 72(11):1457-71.
2. Girard TD, Thompson JL, Pandharipande PP, Brummel NE, Jackson JC, Patel MB, Hughes CG, Chandrasekhar R, Pun BT, Boehm LM, Elstad MR, Goodman RB, Bernard GR, Dittus RS, Ely EW. Clinical phenotypes of delirium during critical illness and severity of subsequent long-term cognitive impairment: a prospective cohort study. *Lancet Respir Med*. 2018; 6(3):213-222.
3. Milbrandt EB, Deppen S, Harrison PL, et al., Costs associated with delirium in mechanically ventilated patients. *Crit Care Med* 2004; 32(4): 955-62.
4. Papathanassoglou E. Recent advances in understanding pain: What lies ahead for critical care? *Nurs Crit Care* 2014; 85(11):1586-93
5. Brame AL, Singer M. Stressing the obvious? An allostatic look at critical illness. *Crit Care Med* 2010; 38(10 Suppl):S600-7
6. Al-Qadheeb NS, Skrobik Y, Schumaker G, et al. Preventing ICU Subsyndromal Delirium Conversion to Delirium With Low-Dose IV Haloperidol: A Double-Blind, Placebo-Controlled Pilot Study. *Crit Care Med* 2016; 44(3):583-91
7. Su X, Meng ZT, Wu XH, Cui F, Li HL, Wang DX, Zhu X, Zhu SN, Maze M, Ma D. Dexmedetomidine for prevention of delirium in elderly patients after non-cardiac

- 1
2
3 surgery: a randomised, double-blind, placebo-controlled trial. *Lancet*; 2016.
4
5 15;388(10054):1893-1902. doi: 10.1016/S0140-6736(16)30580-3.
6
7
8 8. Barr J., Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of
9
10 pain, agitation, and delirium in adult patients in the intensive care unit. *Crit Care Med*
11
12 2013; 41(1): 263-306
13
14
15 9. Trogrlić Z, van der Jagt M, Bakker J, et al. A systematic review of implementation
16
17 strategies for assessment, prevention, and management of ICU delirium and their effect
18
19 on clinical outcomes. *Crit Care* 2015 ;19:157
20
21
22 10. Papathanassoglou, E. D., Giannakopoulou, M., Mpouzika, M., Bozas, E., Karabinis, A.
23
24 Potential effects of stress in critical illness through the role of stress neuropeptides. *Nurs*
25
26 *Crit Care* 2010; 15(4), 204-16.
27
28
29 11. Cuesta, J. M., Singer, M. The stress response and critical illness: A review. *Critical Care*
30
31 *Medicine* 2012; 40(12), 3283-9.
32
33
34 12. Norris, P. R., Ozdas, A., Cao, H., et al. Cardiac uncoupling and heart rate variability
35
36 stratify ICU patients by mortality: A study of 2088 trauma patients. *Ann Surg* 2006;
37
38 243(6), 804-12.
39
40
41 13. Maclullich, A. M., Ferguson, K. J., Miller, T., de Rooij, S. E., & Cunningham, C.
42
43 Unravelling the pathophysiology of delirium: A focus on the role of aberrant stress
44
45 responses. *J Psychosom Res* 2008; 65(3), 229-38.
46
47
48 14. Zaal, I. J., Devlin. J. W., Peelen, L. M., Slooter, A. J. A systematic review of risk factors
49
50 for delirium in the ICU. *Crit Care Med* 2015; 43(1):40-7.
51
52 doi:10.1097/CCM.0000000000000625.
53
54
55
56
57
58
59
60

- 1
2
3 15. Brummel NE, Jackson JC, Pandharipande PP, Thompson JL, Shintani AK, Dittus RS,
4 Gill TM, Bernard GR, Ely EW, Girard TD. Delirium in the ICU and subsequent long-
5 term disability among survivors of mechanical ventilation. *Crit Care Med.*
6 2014;42(2):369-77. doi: 10.1097/CCM.0b013e3182a645bd.
7
8
9
10
11
12 16. Oke, S. L., & Tracey, K. J. The inflammatory reflex and the role of complementary and
13 alternative medical therapies. *Ann NY Acad Sci* 2009; 1172, 172-80.
14
15
16
17 17. Park, E. R., Traeger, L., Vranceanu, A. M., et al. The development of a patient-centered
18 program based on the relaxation response: The Relaxation Response Resiliency Program
19 (3RP). *Psychosomatics* 2013; 54(2), 165-74.
20
21
22
23
24 18. Hadjibalassi, M., Lambrinou, E., Papastavrou, E., Papathanassoglou, E. The effect of
25 guided imagery on physiological and psychological outcomes of adult ICU patients: A
26 systematic literature review and methodological implications. *Austr Crit Care.* 2017; Mar
27 29. pii: S1036-7314(17)30164-9. doi: 10.1016/j.aucc.2017.03.001.
28
29
30
31
32
33 19. Chlan L, Halm MA. Does music ease pain and anxiety in the critically ill? *Am J Crit*
34 *Care.* 2013; 22(6):528-32.
35
36
37
38 20. Papathanassoglou E, Hadjibalassi M, Lambrinou E, Papastavrou E, Paikousis L,
39 Kyprianou T. Pilot Clinical Trial of the effects of an integrative nursing intervention on
40 critically ill patients' pain, hemodynamic measurements, psychological responses and
41 sleep. *Am J of Crit Care* 2018; 27:172-185.
42
43
44
45
46
47 21. Pan W. Sample size and power calculations with correlated binary data. *Control. Clin*
48 *Trials* 2001;22:211-27.
49
50
51
52 22. Moore CG, Carter RE, Nietert PJ, Stewart PW. Recommendations for planning pilot
53 studies in clinical and translational research. *Clin Transl Sci* 2011; 4(5):332-7
54
55
56
57
58
59
60

- 1
2
3 23. Hermann, C. Psychological interventions for chronic pediatric pain: State of the art,
4 current developments and open questions. *Pain Manag* 2011; 1(5), 473-83.
5
6
7
8 24. Dossey, B.M., & Keegan, L. *Holistic Nursing - A Handbook for Practice*. American
9
10
11
12
13 25. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M; Medical Research
14
15
16
17
18
19
20 26. Papathanassoglou ED. Psychological support and outcomes for ICU patients. *Nurs Crit*
21
22
23
24
25
26 27. Diego, M. A., & Field, T. Moderate pressure massage elicits a parasympathetic nervous
27
28
29
30
31 28. Neto AS, Nassar AP Jr, Cardoso SO, et al. Delirium screening in critically ill patients: a
32
33
34
35 29. Papathanassoglou E, Hadjibalassi M, Miltiadous P, Karanikola M. Effects of an
36
37
38
39
40
41
42 30. Robins, J. M., Rotnitzky, A., & Zhao, L. P. Analysis of semiparametric regression
43
44
45
46
47
48
49 31. Onwuegbuzie, A. J., Dickinson, W. B., Leech, N. L., & Zoran, A. G. A qualitative
50
51
52
53
54
55
56
57
58
59
60
- 2009; Retrieved from: <http://creativecommons.org/licenses/by/2.0>

- 1
2
3 32. Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009).
4
5 Research Electronic Data Capture (REDCap) - A metadata-driven methodology and
6
7 workflow process for providing translational research informatics support. *J Biomed*
8
9 *Inform* 2009; 42(2), 377-81.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 **Contributions:** EDEP, YS, KH, JK contributed to study conception, design and manuscript
4 draft. HTS, CN, LR, SB, MM, TP contributed to discussions about design; EDEP, YS, KH, JK,
5 HTS, CN, LR, SB, MM, TP are investigators in the CIHR grant supporting this work. PT
6
7 contributed to refining data collection strategies. CL and RA contributed to the development and
8 teaching of the massage intervention and IH to randomization and statistical analysis plan. TSB
9
10 contributed to the development of the music therapy piece of the intervention. This study is
11 supported by the Canadian Critical Care Trials group. All authors contributed to refinement of
12 the study protocol and approved the final manuscript.
13
14

15
16
17 **Funding:** This work is supported by a Canadian Institutes of Health Research (CIHR) grant
18 (CIHR PS 148850; PI: EP) and an Alberta Innovates Strategy for Patient Oriented Research
19 (SPOR) Support Grant (PI: EP)
20
21

22
23 **Sponsors's contact data:** Canadian Institutes of Health Research, 160 Elgin Street, 9th Floor
24 Address Locator 4809A, Ottawa ON K1A 0W9, Canada; Tel.: 613-941-2672.
25
26

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Alberta Innovates- SPOR Support: 1500, 10104 – 103 Avenue, Edmonton, Alberta, T5J 0H8,
Canada; Tel.: 780-423-5727.

61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
Acknowledgements: The authors are grateful to the participating sites: Royal Alexandra
Hospital, Edmonton, AB, Canada and University of Alberta Hospital, General Systems ICU,
Edmonton, AB, Canada. We would like to acknowledge the support of the Consultation and
Research Services Platform at The Alberta' SPOR SUPPORT Unit in the statistical services. We
wish to thank the Epidemiology Coordinating Research Centre (EPICORE), University of
Alberta, for statistics consultation, and Lily Yushko, systems analyst EPICORE for development
of patient report forms, and Thilini Herath Mudiyansele for contributions to the final version
of the manuscript.

Authors' conflict of interest: None declared

Data Statement: Technical appendix, statistical code, and dataset will be available from EPICORE, University of Alberta.

Legends

Figure 1.

Evidence-based framework for the physiological mechanism implicated in relaxation-induced effects in critical illness. Relaxation acts early at the pathophysiological cascade through which an exaggerated stress response results in pro-inflammatory effects, suppressed PNS outflow and subsequently in systemic inflammation, multiple organ dysfunction and death. The relaxation response counterbalances the exaggerated stress response and activates PNS and cholinergic anti-inflammatory signaling, which downregulates pro-inflammatory (e.g., HMGB-1) and up-regulates anti-inflammatory cytokines; therefore attenuating systemic inflammation and its detrimental organ effects. ($\alpha 7$ -nAChR: *alpha7-nicotinic acetylcholine receptor*, HMGB-1: *High Mobility Group Box-1*; PNS: *Parasympathetic Nervous System*)


Figure 2:

Schematic of study design. (*Ach*: *Acetylcholine*, *AE*: *Adverse Event*, *APACHE*: *Acute Physiology & Chronic Health Evaluation*, *CPOT*: *Critical Care Pain Observation Tool*, *CRP*: *C-Reactive Protein*, *EQ-5D*: *EuroQol Five Dimensions Questionnaire*, *HADS*: *Hospital Anxiety and Depression Scale*, *HF*: *High Frequency*, *HMGB*: *High Mobility Group Box*, *HRV*: *Heart Rate Variability*, *ICDSC*: *Intensive Care Delirium Screening Checklist*, *ICU*: *Intensive Care Unit*, *IQCODE*: *Informant Questionnaire on Cognitive Decline in the Elderly*, *IV*: *Intravenous*,


1
2
3 *LF: Low Frequency, LOS : Length of Stay, NRS: Numeric Rating Scale, RASS: Richmond*
4
5 *Agitation Sedation Scale, RGI: Relaxation and Guided Imagery, S-R: Self-Reported, SOFA:*
6
7 *Sequential Organ Failure, STAI: State Trait Anxiety Inventory).*
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



279x361mm (300 x 300 DPI)



279x361mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Primary Outcome: ICDSC≥4													
Secondary outcomes: <i>ICDSC, ICDSC:1-3, RASS, daily sedatives/analgesics/antipsychotics dose, sleep NRS, sleep duration, APACHE II, SOFA</i>	X	X	X	X	X	X	X						
		pre-post-Intervention											
C-POT, PAIN NRS, pain distress NRS, stress NRS, HF- LF HRV	X	X2	X2	X2	X2	X2							
		pre-post-Intervention											
HMGB-1, CRP, Ach		X2	X2	X2	X2	X2							
ICU LOS, duration MV, ICU survival								X					
HADS									X				
Hospital survival, Hospital LOS										X			
											X		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

6 week survival, Interview, EQ-5D, SF-36										
4-month survival, EQ-5D, SF-36										X

Ach: Acetylcholine, CPOT: Critical Care Pain Observation Tool, CRP: C-Reactive Protein, DEMMI: de Morton Mobility Index, EQ-5D: EuroQol Five Dimensions Questionnaire, HADS: Hospital Anxiety and Depression Scale, HF: High Frequency, HMGB: High Mobility Group Box, HRV: Heart Rate Variability, ICDSC: Intensive Care Delirium Screening Checklist, ICU: Intensive Care Unit, Interview: Qualitative open ended questions; IQCODE: Informant Questionnaire on Cognitive Decline in the Elderly, LF: Low Frequency, LOS : Length of Stay, MV: mechanical ventilation, NRS: Numeric Rating Scale, RASS: Richmond Agitation Sedation Scale, RGI: Relaxation and Guided Imagery, S-R: Self-Reported, SOFA: Sequential Organ Failure, STAI: State Trait Anxiety Inventory.

For Peer review only

136/bmjopen-2018-023961 on 15 January 2019. Downloaded from <http://bmjopen.bmj.com/> on April 27, 2024 by guest. Protected by copyright.

1
2
3 **Appendix 2.** Telephone interview guide (Qualitative open-ended questions)
4
5
6
7
8

- 9 1. Do you remember listening to music while in the ICU? Can you describe what you
10 remember?
11
12
13 2. Do you remember listening to a voice through the headphones? Can you describe what
14 you remember?
15
16
17 3. If yes, how did this make you feel? Were you able to follow the instructions with your
18 mind/ imagination? Please describe
19
20
21 4. Do you remember somebody giving you a massage? Can you describe what you
22 remember?
23
24
25 5. If yes, how did this make you feel?
26
27
28 6. Would you wish to receive this intervention again? Why?
29
30
31 7. Would you recommend this intervention for other patients? Why?
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	2
Protocol version	#3	Date and version identifier	2
Funding	#4	Sources and types of financial, material, and other support	22
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	22
Roles and	#5b	Name and contact information for the trial sponsor	22

responsibilities:			
1 sponsor contact			
2 information			
3			
4			
5 22Roles and	#5c	Role of study sponsor and funders, if any, in study	22
6 responsibilities:		design; collection, management, analysis, and	
7 sponsor and funder		interpretation of data; writing of the report; and the	
8		decision to submit the report for publication,	
9		including whether they will have ultimate authority	
10		over any of these activities	
11			
12			
13			
14			
15 Roles and	#5d	Composition, roles, and responsibilities of the	14-15
16 responsibilities:		coordinating centre, steering committee, endpoint	
17 committees		adjudication committee, data management team,	
18		and other individuals or groups overseeing the	
19		trial, if applicable (see Item 21a for data	
20		monitoring committee)	
21			
22			
23			
24			
25 Background and	#6a	Description of research question and justification	4-5
26 rationale		for undertaking the trial, including summary of	
27		relevant studies (published and unpublished)	
28		examining benefits and harms for each	
29		intervention	
30			
31			
32			
33 Background and	#6b	Explanation for choice of comparators	5
34 rationale: choice of			
35 comparators			
36			
37			
38			
39 Objectives	#7	Specific objectives or hypotheses	5, 6
40			
41 Trial design	#8	Description of trial design including type of trial	5
42		(eg, parallel group, crossover, factorial, single	
43		group), allocation ratio, and framework (eg,	
44		superiority, equivalence, non-inferiority,	
45		exploratory)	
46			
47			
48			
49 Study setting	#9	Description of study settings (eg, community clinic,	6
50		academic hospital) and list of countries where	
51		data will be collected. Reference to where list of	
52		study sites can be obtained	
53			
54			
55			
56 Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If	7
57		applicable, eligibility criteria for study centres and	
58			
59			
60			

		individuals who will perform the interventions (eg, surgeons, psychotherapists)	
Interventions: description	#11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	7-8,9
Interventions: modifications	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	8
Interventions: adherence	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	8
Interventions: concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	9
Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	10-12
Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	1. Appendix
Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	6-7
Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size	6
Allocation:	#16a	Method of generating the allocation sequence (eg,	8

1	sequence		computer-generated random numbers), and list of	
2	generation		8any factors for stratification. To reduce	
3			predictability of a random sequence, details of any	
4			planned restriction (eg, blocking) should be	
5			provided in a separate document that is	
6			unavailable to those who enrol participants or	
7			assign interventions	
8				
9				
10				
11	Allocation	#16b	Mechanism of implementing the allocation	8
12	concealment		sequence (eg, central telephone; sequentially	
13	mechanism		numbered, opaque, sealed envelopes), describing	
14			any steps to conceal the sequence until	
15			interventions are assigned	
16				
17				
18				
19	Allocation:	#16c	Who will generate the allocation sequence, who	8
20	implementation		will enrol participants, and who will assign	
21			participants to interventions	
22				
23				
24				
25	Blinding (masking)	#17a	Who will be blinded after assignment to	8-9
26			interventions (eg, trial participants, care providers,	
27			outcome assessors, data analysts), and how	
28				
29				
30	Blinding (masking):	#17b	If blinded, circumstances under which unblinding	9, NA
31	emergency		is permissible, and procedure for revealing a	
32	unblinding		participant's allocated intervention during the trial	
33				
34				
35				
36	Data collection plan	#18a	Plans for assessment and collection of outcome,	9-10
37			baseline, and other trial data, including any related	
38			processes to promote data quality (eg, duplicate	
39			measurements, training of assessors) and a	
40			description of study instruments (eg,	
41			questionnaires, laboratory tests) along with their	
42			reliability and validity, if known. Reference to	
43			where data collection forms can be found, if not in	
44			the protocol	
45				
46				
47				
48				
49				
50	Data collection	#18b	Plans to promote participant retention and	9
51	plan: retention		complete follow-up, including list of any outcome	
52			data to be collected for participants who	
53			discontinue or deviate from intervention protocols	
54				
55				
56				
57	Data management	#19	Plans for data entry, coding, security, and storage,	9,15
58			including any related processes to promote data	
59				
60				

1		quality (eg, double data entry; range checks for	
2		data values). Reference to where details of data	
3		management procedures can be found, if not in	
4		the protocol	
5			
6			
7	Statistics:	#20a Statistical methods for analysing primary and	13-14
8	outcomes	secondary outcomes. Reference to where other	
9		details of the statistical analysis plan can be	
10		found, if not in the protocol	
11			
12			
13			
14	Statistics: additional	#20b Methods for any additional analyses (eg, subgroup	13-14
15	analyses	and adjusted analyses)	
16			
17			
18	Statistics: analysis	#20c Definition of analysis population relating to	14
19	population and	protocol non-adherence (eg, as randomised	
20	missing data	analysis), and any statistical methods to handle	
21		missing data (eg, multiple imputation)	
22			
23			
24	Data monitoring:	#21a Composition of data monitoring committee (DMC);	14-15
25	formal committee	summary of its role and reporting structure;	
26		statement of whether it is independent from the	
27		sponsor and competing interests; and reference to	
28		where further details about its charter can be	
29		found, if not in the protocol. Alternatively, an	
30		explanation of why a DMC is not needed	
31			
32			
33			
34			
35			
36	Data monitoring:	#21b Description of any interim analyses and stopping	NA
37	interim analysis	guidelines, including who will have access to	
38		these interim results and make the final decision	
39		to terminate the trial	
40			
41			
42	Harms	#22 Plans for collecting, assessing, reporting, and	16
43		managing solicited and spontaneously reported	
44		adverse events and other unintended effects of	
45		trial interventions or trial conduct	
46			
47			
48			
49	Auditing	#23 Frequency and procedures for auditing trial	8,15
50		conduct, if any, and whether the process will be	
51		independent from investigators and the sponsor	
52			
53			
54			
55	Research ethics	#24 Plans for seeking research ethics committee /	15,16
56	approval	institutional review board (REC / IRB) approval	
57			
58			
59	Protocol	#25 Plans for communicating important protocol	15

1	amendments		modifications (eg, changes to eligibility criteria,	
2			outcomes, analyses) to relevant parties (eg,	
3			investigators, REC / IRBs, trial participants, trial	
4			registries, journals, regulators)	
5				
6				
7	Consent or assent	#26a	Who will obtain informed consent or assent from	15-16
8			potential trial participants or authorised	
9			surrogates, and how (see Item 32)	
10				
11				
12	Consent or assent:	#26b	Additional consent provisions for collection and	16
13	ancillary studies		use of participant data and biological specimens in	
14			ancillary studies, if applicable	
15				
16				
17	Confidentiality	#27	How personal information about potential and	16
18			enrolled participants will be collected, shared, and	
19			maintained in order to protect confidentiality	
20			before, during, and after the trial	
21				
22				
23				
24	Declaration of	#28	Financial and other competing interests for	22
25	interests		principal investigators for the overall trial and each	
26			study site	
27				
28				
29				
30	Data access	#29	Statement of who will have access to the final trial	NA
31			dataset, and disclosure of contractual agreements	
32			that limit such access for investigators	
33				
34				
35	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care,	NA
36	trial care		and for compensation to those who suffer harm	
37			from trial participation	
38				
39				
40	Dissemination	#31a	Plans for investigators and sponsor to	16
41	policy: trial results		communicate trial results to participants,	
42			healthcare professionals, the public, and other	
43			relevant groups (eg, via publication, reporting in	
44			results databases, or other data sharing	
45			arrangements), including any publication	
46			restrictions	
47				
48				
49				
50				
51	Dissemination	#31b	Authorship eligibility guidelines and any intended	NA
52	policy: authorship		use of professional writers	
53				
54				
55	Dissemination	#31c	Plans, if any, for granting public access to the full	16
56	policy: reproducible		protocol, participant-level dataset, and statistical	
57	research		code	
58				
59				
60				

1 2 3 4 5	Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	Upon request
6 7 8 9 10 11 12	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	12-13 & upon request

The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Relaxation for Critically ill Patient Outcomes and Stress-coping Enhancement (REPOSE): A protocol for a pilot randomized trial of an integrative intervention to improve critically ill patients' delirium and related outcomes

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023961.R2
Article Type:	Protocol
Date Submitted by the Author:	12-Oct-2018
Complete List of Authors:	Papathanassoglou, Elizabeth; University of Alberta, Faculty of Nursing Skrobik, Yoanna; McGill University, Medicine Hegadoren, Kathleen; University of Alberta, Faculty of Nursing Thompson, Patrica; 3. Royal Alexandra Hospital, Edmonton, AB, Canada, Critical Care Medicine Stelfox, Henry; University of Calgary, Critical Care Medicine Norris, Colleen; University of Alberta, Faculty of Nursing Rose, Louise; University of Toronto, Lawrence S. Bloomberg Faculty of Nursing Bagshaw, Sean; University of Alberta, Critical Care Medicine, Faculty of Medicine & Dentistry Meier, Michael; University of Alberta, Critical Care Medicine, Faculty of Medicine & Dentistry LoCicero, Cheryl Ashmore, Rhonda Sparrow Brulotte, Tiffany ; University of Alberta Hassan, Imran; University of Alberta, EPICORE Park, Tanya; University of Alberta, Faculty of Nursing Kutsogiannis, Demetrios J; University of Alberta, 2. Department of Critical Care Medicine, Faculty of Medicine and Dentistry
Primary Subject Heading:	Intensive care
Secondary Subject Heading:	Complementary medicine, Nursing
Keywords:	critical illness, music therapy, relaxation, guided imagery, delirium, complex intervention

SCHOLARONE™
Manuscripts

Relaxation for Critically ill Patient Outcomes and Stress-coping Enhancement (REPOSE):

A protocol for a pilot randomized trial of an integrative intervention to improve critically ill patients' delirium and related outcomes

Elizabeth D.E. Papathanassoglou, RN, PhD^{1*}, Yoanna Skrobik, MD FRCP(c) MSc FCCP⁴, Kathleen Hegadoren, RN, PhD¹, Patrica Thompson, RN, CCRP³, Henry T. Stelfox, MD, PhD⁵, Colleen Norris, RN, PhD¹, Louise Rose, RN, PhD^{6,7}, Sean Bagshaw, MD, PhD^{2,8}, Michael Meier, MD, PhD^{2,8}, Cheryl LoCicero, BSc⁹, Rhonda Ashmore, MScPT¹⁰, Tiffany Sparrow Brulotte, MTA¹¹, Imran Hassan, MSc¹², Tanya Park, RN, PhD¹, Demetrios J. Kutsogiannis MD MHS FRCPC^{2,3}

1. University of Alberta, Faculty of Nursing, Edmonton, AB, Canada
2. Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
3. Royal Alexandra Hospital, Edmonton, AB, Canada
4. Department of Medicine, McGill University; Regroupement de Soins Critiques Respiratoires, FRQS
5. Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
6. Sunnybrook Health Sciences Centre, Toronto, ON, Canada
7. King's College London, London, UK
8. University of Alberta Hospital, General Systems ICU, Edmonton, AB, Canada
9. Registered Massage Therapist (RMT), Certified Advanced Rolfer
10. Registered Massage Therapist (RMT), PT
11. Accredited music therapist (BMT, MTA), MA candidate in ethnomusicology
12. Biostatistician, EPICORE Centre, University of Alberta

(*): To whom correspondence should be addressed.

Key words: critical illness, music therapy, relaxation, guided imagery, autonomic nervous system, delirium, complex intervention

Word count: 4,695

Correspondence: Elizabeth D. E. Papathanassoglou, University of Alberta, Faculty of Nursing, 5-262 Edmonton Clinic Health Academy (ECHA), 11405-87th Ave. Edmonton, Alberta, Canada T6G 1C9, Tel.: (780) 492-5674 (w), (780) 237-9375 (c), e-mail: papathan@ualberta.ca

REPOSE 1

Abstract

Introduction: Delirium is a common complication of critical illness, associated with negative patient outcomes. Preventive or therapeutic interventions are mostly ineffective. Although relaxation-inducing approaches may benefit critically ill patients, no well-designed studies target delirium prevention as a primary outcome. The objective of this study is to assess feasibility and treatment effect estimates of a multimodal integrative intervention incorporating relaxation, guided imagery, and moderate pressure touch-massage for prevention of critical illness delirium and for related outcomes.

Methods and analysis: Randomized, controlled, single-blinded trial with 2 parallel groups (1:1 allocation: intervention and standard care) and stratified randomization [age (18-64, ≥ 65), presence of trauma) with blocking, involving 104 patients with Intensive Care Delirium Screening Checklist (ICDSC): 0-3 recruited from 2 academic ICUs. Intervention group participants receive the intervention in addition to standard care for up to 5 consecutive days (or until transfer/discharge); control group participants receive standard care and a sham intervention. We will assess pre-defined feasibility outcomes, i.e., recruitment rates, protocol adherence. The primary clinical outcome is incidence of delirium (ICDSC ≥ 4). Secondary outcomes include pain scores, inflammatory biomarkers, heart rate variability, stress and quality of life (6 weeks; 4 months) post-ICU discharge. Feasibility measures will be analyzed descriptively, and outcomes longitudinally. Estimates of effects will be calculated.

Ethics and dissemination: The study has received approval from the Human Research Ethics Board, University of Alberta. Results will inform the design of a future multi-center trial.

REPOSE 2

Registration: clinicaltrials.gov (NCT02905812).

Protocol date: March 3, 2018, version 5, Protocol amendment number: 07

Primary reasons for amendment: Refining feasibility of intervention and data collection.

Summary

Strengths and limitations of this study

- We will test feasibility and measures of effect of a previously piloted relaxation-inducing intervention for the prevention of delirium and improvement of related outcomes in critically ill patients.
- We will employ an evidence-based, non-pharmacological multimodal integrative intervention that has shown effectiveness for reducing pain and improving a number of secondary outcomes in a previous pilot study.
- This pilot aims to assess estimates of effect and feasibility to inform a future trial.
- Although clinicians and outcome assessors will be blinded, due to the nature of the intervention, participants and nurses providing direct care to patients cannot be blinded to allocation, although they will be blinded to the study hypotheses.
- The mechanisms of effects of relaxation-inducing interventions in critical illness are not well understood; hence, we aim to explore effects of the intervention on parasympathetic system activation and inflammatory markers.

REPOSE 3

For peer review only

REPOSE 4

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

ICU delirium affects 35-55% of critically ill patients, and is independently associated with a 13-fold (adjusted odds ratio (OR):4.88-13.0) increased risk of death (1) and long-term cognitive impairment (2). ICU delirium carries important financial and societal burdens [(39% higher adjusted ICU (95% CI:12-72%), and 31% higher hospital costs (95% CI:1-70%)] (3). Moreover, patients identify frightening delirium experiences and pain as the most severe stressors (4,5) in critical care. Pharmacological interventions for the prevention and treatment of delirium have limited benefit and are associated with high costs and risks for side effects (6,7). Although clinical guidelines recommend the development of non-pharmacological interventions to prevent delirium (8), effective prevention strategies have yet to be established (9).

A prolonged and eventually aberrant stress response and depressed parasympathetic (PNS) activity have been postulated as the pathophysiological basis for the development of both ICU delirium and systemic inflammation (10-13). Frightening hallucinations and ideations during delirium may further exaggerate the stress-response and prolong critical illness with detrimental consequences. Pain may worsen matters by reciprocal incremental feed-back on inflammation and stress (4, 14). Thus, in critical illness, stress, delirium, pain and systemic inflammation may comprise a self-perpetuating syndrome. Attenuating the cascade of negative health impacts from pain and delirium has become a high clinical priority (Figure 1) (8).

Moreover, the growing recognition that delirium and other critical illness sequelae may have long term consequences in critical illness survivors (15) further highlights the need for prevention strategies.

REPOSE 5

Evidence-based theoretical work postulates that the multitude of psychological stressors in critically ill individuals may contribute to the development of pathophysiologic sequelae (10). Moreover, animal models illustrate that PNS stimulation and acetylcholine (ACh) release suppress inflammation and decrease fatality, via the cholinergic anti-inflammatory pathway (16). Devising ways to draw on the autonomic nervous systems' inflammation- and stress-regulatory properties by non-pharmacological interventions has, in theory, the potential to improve outcomes with low side-effect risk. However, stimulation of the PNS in critical care is challenging. Relaxation-inducing interventions can induce PNS activity. Such approaches have successfully been used in diverse patient populations to counter stress, but remain under-tested in critical illness (17). A recent systematic review shows favorable effects of relaxation and guided imagery intervention in reducing pain, anxiety and length of stay in critically ill patients (18); whereas, the relaxation inducing effects of music in critical care have been well supported by evidence (19). In a pilot randomized controlled trial (RCT) of the effects of a similar multi-modal intervention on the incidence of pain and on a number of secondary outcomes, we observed significant decreases in pain incidence (RR=0.56, p=0.003) and severity (p<0.0001), systolic arterial pressure, anxiety, along with improved sleep quality (20).

Hypotheses

Overall, we hypothesize that a multimodal intervention incorporating relaxation and guided imagery (RGI) and moderate pressure touch-massage is feasible within a critical care setting, and can have an effect on decreasing delirium and in improving physiological and psychological outcomes in randomized critically patients who will receive standard care and the intervention compared to patients receiving standard care plus a sham intervention only.

Primary Hypotheses:

We hypothesize that the intervention will be feasible and that it will have an effect on decreasing delirium incidence and duration.

Secondary hypotheses:

We hypothesize that the intervention will have an effect on: a) incidence rate of subsyndromal delirium, time to delirium occurrence, proportion of delirium-free time during up to 8 days of ICU stay; b) sedation levels and daily sedative, analgesic and antipsychotic agent dose; c) pain occurrence and intensity; d) perceived stress level; e) sleep duration and quality; f) anxiety; g) length of ICU stay and duration of mechanical ventilation/ proportion of mechanical ventilation-free days; h) hospital LOS, i) physiological biomarkers; and k) quality of life after ICU discharge.

Design and Methods

Study design

Relaxation for Critically ill Patient Outcomes and Stress-coping Enhancement (REPOSE) is a pilot feasibility, randomized, controlled, single-blinded trial with 2 parallel groups (intervention and standard care). Accounting for major risk factors of delirium (15), stratified randomization according to age (18-64, ≥ 65) and presence of either surgical or trauma injury with blocking and 1:1 allocation to assure balance in numbers per group will be employed.

Research Objectives

Research objectives include to:

a) Assess clinical trial feasibility with pre-defined goals (enrolment, randomization, adherence, timing of intervention, workload)

REPOSE 7

- 1
- 2
- 3 b) Calculate estimates and variance of treatment effect across outcome measures
- 4
- 5
- 6 c) Calculate Confidence Intervals (CI) of incidence proportions, means and Standard Deviation
- 7
- 8 (SD) of outcome measures in study groups, and
- 9
- 10
- 11 d) Explore the feasibility of identifying underlying physiological mechanisms
- 12
- 13

14 *Setting, recruitment and sample size*

15
16
17
18 Consecutive patients admitted to 2 academic ICUs, in Edmonton, AB, Canada, with an ICDSC
19 score of 0-3 will be screened for study eligibility and will be recruited by research staff at each
20 site. In cases where an ICDSC score cannot be obtained on admission, we will screen patients for
21 up to 4 days after admission. Since delirium occurs most often within the first 5 days of admission,
22 screening and enrolment will take place as soon as possible and within 96 hours after ICU
23 admission. This pilot is not powered to determine a difference in a primary outcome, since
24
25 we aim to assess estimates of effect. For a definitive trial, we would require 290 (145/arm)
26 patients to detect a 10% difference in incidence proportion between intervention (20%)
27 and control (30%) arm (two-sided $\alpha=0.05$, power=80%, drop-out rate=10%). The Pan
28 method (21), which is based on generalized estimating equations, was used to perform
29 the sample size calculation under the assumption of AR(1) correlation structure among 5
30 days repeated measurements with correlation between any two adjacent observations from the
31 same subject of 0.5. Since this is a pilot, aiming to explore feasibility and estimates of effects, and
32 the incidence rates used for the calculation might not be appropriate, we used 36% of the sample
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

58 *REPOSE 8*

1
2
3 size of the full study to estimate the parameters accurately and get an experience for a full trial
4
5 (22).
6
7

8 9 *Eligibility*

10
11
12 Inclusion criteria: a) Age over 18 years, b) ICDSC:0-3, c) written informed consent, by
13
14 participant or by family member/ surrogate in case participant not capable.
15
16
17

18
19 Exclusion Criteria: Patients: a) Already in the ICU for more than 96 hours, b) with
20
21 ICDSC>3 within 72 h of screening in case intervention has not been initiated, c) on special
22
23 contact precautions (i.e., MRSA, VRE, HIV), d) with expected Intensive Care Unit (ICU)
24
25 Length of stay (LOS) < 72 hours, e) with acute neurological illness/ neurological trauma, persistent
26
27 deep sedation or coma [Richmond Agitation Sedation Scale (RASS = -4, -5)] f) with current
28
29 history of severe mental health problems and dementia, as per history, g) with hearing impairment
30
31 or conditions not permitting use of headphones, h) on neuro-muscular blockers, i) with known or
32
33 suspected substance/ alcohol withdrawal, and j) enrolled in trials of sedatives, antipsychotics.
34
35
36
37
38
39
40
41

42 *Patient and Public involvement*

43
44
45 The protocol is based on a pilot study with 60 randomized patients (20), 12 of which provided
46
47 feedback regarding the desirability, burden and specific components of the intervention, study
48
49 procedures and preferred outcomes. Participants' feedback informed the design of the study,
50
51 resulting in many significant changes. Preferred post-ICU follow-up times were informed by an
52
53 informal advisory group through the Alberta Innovates Strategy for Patient Oriented Research
54
55
56

57
58
59
60
REPOSE 9

1
2
3 (SPOR) network of patient representatives. Moreover, as a patient and clinician engagement
4
5
6
7 strategy, an advisory group with representatives of patients, families and clinicians will
8
9
10 act as a consultation group for the research team. Acceptance and desirability of the
11
12
13 protocol by clinicians and patients/ families will be assessed further by focus group
14
15
16 discussions. Recommendations will inform future development of the intervention and
17
18
19 research design. Canadian Institutes of Health Research (CIHR) guidelines for patient
20
21
22 engagement will be used to establish and facilitate the advisory group. Feedback on: a)
23
24
25 concerns on the intervention, study processes, contamination of the control group by
26
27
28 implementation of aspects of the intervention, b) desirability of intervention (massage,
29
30
31 music choices, complexity, voice of recording, pace), c) timing within the day, d)
32
33
34 duration/ feasibility of the intervention, e) burden of study processes, f) outcomes to be
35
36
37 addressed in the future trial, g) interpretation of results, h) strategies for dissemination
38
39
40
41
42
43
44
45 of findings will be collected.
46
47
48

49 **Intervention**

50
51
52 The choice of a multimodal intervention (duration: 55min) was based on an evidence-based
53
54
55 literature review, its superiority to unidimensional approaches (23), the recommendations of the
56
57

58 *REPOSE 10*

American Holistic Nurses Association (24) and a successful pilot (20). According to the UK Medical Research Council (MRC) guidance for complex intervention trials (25), development of the protocol included extensive theoretical work (10), two systematic reviews (18, 26), modeling of outcomes, extensive consultations with groups of experts, one small feasibility and acceptability pilot (n=10 participants) and one larger pilot (n=60) (20) and consultation with pilot participants and patients' representatives. The intervention has been developed by the research team and a group of experts based at the University of Alberta and Cyprus University of Technology. It includes: a) a brief moderate pressure massage session (massage: 15 minutes), b) relaxation and guided imagery (30 minutes, through headphones). The 30 min recorded RGI intervention involves: a) guided relaxation, b) a structured guided imagery script supported by instrumental music, and c) recorded instrumental music for 15 minutes (Haydn concerto no 1 in C major and Bach violin concerto in D minor, 60 beats per min approximately). The same recorded RGI script will be used at all sessions. It includes positive suggestions and instructions for gradual relaxation, followed by guidance to visualize one's body being healed. Moderate pressure (4 N, approximately or patient pressure rating 3/10) low velocity (1-5cm/second) massage consists of broad and repetitive circular movements with wide area of contact, applied sequentially for 2-3 minutes at each site: hands, forearms, lateral arms, and then over trapezius muscles, the temple, scalp, face and forehead area. Areas are to be contacted as appropriate to each participant, and the protocol may be adapted taking into account safety issues (i.e., to avoid area around intravascular catheter or injury). Moderate pressure massage is involved in PNS activation, in contrast to light pressure (27). The intervention will be administered once daily (09:00-15:00) for up to 5 consecutive days by trained research staff not involved in patient care, who will be randomly audited by the Trial Steering Committee (TSC) to ensure protocol

REPOSE 11

1
2
3 adherence. The decision to deliver the intervention for the first 5 days after enrollment only was
4 based on epidemiological data regarding the onset of delirium (9), data on median length of stay
5
6 of the target populations in the study institutions and cost considerations. However, it will be
7
8 important to study the effect of the intervention on longer stay patients in future trials. The
9
10 decision to deliver only one intervention daily was based on a small acceptability/ feasibility
11
12 pilot, and pragmatic considerations for knowledge translation and future implementation of this
13
14 approach, as well as cost considerations and burden to participants and units. The durations of
15
16 guided imagery, music listening and touch intervention were based on the acceptability pilot,
17
18 expert opinions on the minimum duration to achieve a relaxation effect and on published
19
20 evidence (18). Despite evidence on the importance of providing choice to patients regarding
21
22 music listening (19), we will use standardized music for intervention stability purposes. It will be
23
24 important to look at the effect of patient-directed music in future trials of this intervention.
25
26
27
28
29

30
31 Interruptions and deviations from the intervention protocol will be recorded in detail. The
32
33 intervention will be terminated upon a patient's transfer or discharge from the ICU. The
34
35 intervention may be discontinued in case of adverse events related to the intervention or
36
37 withdrawal of consent. If we observe ICDSC scores above 3 once the intervention has been
38
39 commenced, the intervention will be continued, unless otherwise indicated by a participant's
40
41 condition. Although, contamination of the control group by spontaneously mimicking aspects of
42
43 the intervention by health care personnel cannot be excluded, health care providers in the units
44
45 are very familiar with clinical trials and have been instructed on the need to abstain from
46
47 mimicking the intervention. Additionally, the touch component of the intervention requires
48
49 specific training and it is unlikely to be successfully replicated.
50
51
52
53
54

55 *Randomization and allocation concealment*

56
57
58
59
60
REPOSE 12

1
2
3 Participants will be randomly assigned to either control or intervention group (1:1 allocation) as
4 per a computer-generated randomization schedule, generated by the Epidemiology Coordinating
5 Research Centre (EPICORE), University of Alberta (UofA), stratified by site, age (18-64, ≥ 65),
6 and presence of surgery or trauma using permuted blocks of random sizes. The block size will not
7 be disclosed to ensure concealment. After baseline measurements, allocation will be disclosed only
8 to the intervention staff. Codes will be generated prior to the beginning of the study by EPICORE.
9
10
11
12
13
14
15
16

17 *Blinding*

18
19
20 Investigators, physicians and nurses (when possible), data collectors, research assistants, and
21 laboratory technicians will be blinded to group allocation during the trial and analysis. Due to the
22 nature of the intervention, participants cannot be blinded to allocation. Also, participants'
23 primary nurses cannot be blinded to study procedures (i.e., delivery of massage);
24 however, they will remain blinded to study hypotheses, study design (i.e., study
25 outcomes, numbers and types of participants' groups), to minimize performance bias. We
26 believe that these procedures along with the sham intervention will maintain an adequate
27 level of concealment even among participants' primary nurses, to minimize bias. The same
28 intervention personnel will be involved in the delivery of the intervention and sham intervention.
29 Intervention personnel are not involved in assessment of patient outcomes, and have been trained
30 on the importance of preserving blinding, therefore minimizing the risk for potential bias.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 *Treatment arms*

1
2
3 Patients randomly allocated to the intervention group will receive the intervention in addition to
4 standard care (standard care + multimodal intervention group). Patients allocated to the control
5
6 standard care (standard care + multimodal intervention group). Patients allocated to the control
7
8 group will receive standard care and a sham intervention consisting of presence of a research staff
9
10 at the bedside with drawn curtains and silent headphones (standard care + sham intervention group;
11
12 Schematic of study design in Figure 2).
13

14 15 *Concomitant care*

16
17
18 Standard care will be continued for all participants. Type and dose of all administered sedative,
19
20 psychoactive and analgesic medication will be recorded.
21
22

23 24 *Duration of participation*

25
26 The total duration may vary according to ICU length of stay and will be 17 weeks approximately,
27
28 from enrolment until the last follow up at 4 months post-ICU discharge.
29
30

31 32 **Data Collection and Instruments**

33
34
35 Data will be collected for each participant by blinded data collectors and captured in a Research
36
37 Electronic Data Capture (RedCap®) database developed and monitored by EPICORE. Time points
38
39 include: baseline measurements, follow-up while in the ICU for up to 5 days, follow up 48-96
40
41 hours after ICU discharge, follow-up 6 weeks and 4 months after ICU discharge. In case of
42
43 participants who discontinue participation, data already collected will be retained.
44
45

46
47 All study scales are routinely used in clinical practice and have established psychometric
48
49 properties. The ICDSC is one of the most reliable tools for assessment of ICU delirium
50
51 advocated by recent guidelines (4, 28). Inter-observer reliability of and sensitivity (80.1, 95%
52
53 CI:73.3-85.8) of ICDSC have been established and will be further assessed in this study (28). For
54
55

56
57
58
59
60
REPOSE 14

1
2
3
4 comatose, deeply sedated patients [Richmond Agitation Sedation Scale (RASS = -4, -5)]
5
6
7 delirium cannot be assessed. Data captured on Case Reports Forms are included in Figure 2.
8
9 Baseline data captured at enrolment will include: Sociodemographic data, admission diagnosis,
10
11 history of alcohol use, medications prior to admission, metabolic acidosis, ICDSC, RASS, Short
12
13 Form Informant Questionnaire on Cognitive Decline in the Elderly (Short IQCODE), Pre-Deliric
14
15 Delirium Risk Score, baseline IV sedation, analgesia and antipsychotic dose, disease severity at
16
17 admission (Acute Physiology & Chronic Health Evaluation II (APACHE II), Sequential Organ
18
19 Failure Assessment: SOFA), number of days in hospital and ICU prior to protocol enrolment.
20
21 For pain, scores obtained at the first pre-intervention measurement will be considered as
22
23 baseline.
24
25
26
27

28 Outcome Measures

29
30
31 Primary and secondary outcome, as well as feasibility, measures include (Appendix 1):
32

33
34 **A. Primary clinical outcome:** a) Incidence rate of delirium (ICDSC ≥ 4), during 5 days of
35
36 intervention (first 5 days of enrolment). Presence of delirium will be assessed by blinded
37
38 trained nurse assessors 2 times daily (8am, 8pm).
39

40
41 **B. Secondary outcomes** [Estimates, variance of effects, proportions and means, SD (where
42
43 applicable) per group]:
44

45 **1. Delirium related secondary outcomes:** a) Incidence rate of delirium (ICDSC ≥ 4) during
46
47 ICU stay and post-intervention, b) incidence rate of subsyndromal delirium (ICDSC: 1-
48
49 3) during the intervention period and subsequent ICU stay, c) time to delirium
50
51 occurrence, d) proportion of delirium-free time during up to 8 days of ICU stay
52
53 (excluding periods with deep sedation, coma), e) Sedation levels (Richmond Agitation
54
55
56
57

REPOSE 15

Sedation Scale (RASS) score, f) Daily sedative (benzo-equivalents and propofol), analgesic (morphine equivalents) and antipsychotic agent (type, mg/24 hours) dose.

2. Pain related outcomes (Pre- and post-intervention): a) Pain intensity (self-reported (S-R) numeric rating scale (NRS) for patients able to self-report, pain indicators (Critical Care Pain Observation Tool (CPOT) in patients unable to self-report, b) perceived stress level (S-R NRS).
3. Sleep (Daily): a) Sleep quality (S-R NRS), b) sleep duration (in minutes) [(sleep monitors (Fitbit Alta HR: daily sleep cycle) and nurses' log (duration of sleep between 7pm-7 am)]. Although more reliable, due to considerations around burden to the unit and cost, we do not use polysomnography in this pilot.
4. Disease severity (Daily): Sequential Organ Failure (SOFA) score
5. Physiological Biomarkers (Pre- & post-intervention): a) Serum Inflammation biomarkers [High-mobility-group-box 1 (HMGB-1), C-reactive protein (CRP) levels, b) High (HF) and low frequency (LF) components of heart rate variability (HRV) as measures of PNS status, c) Serum ACh levels, as a measure of PNS activation. The choice of biomarkers was based on the theoretical framework guiding this work (triggering of a relaxation parasympathetic response and attenuation of the inflammatory response; Figure 1), and results of the pilot study (20, 29), which showed alterations in biomarkers immediately post-intervention and over-time, despite great variability in biomarker levels. The results will help us generate more informed hypotheses for a subsequent trial.
6. Psychological outcomes (2-7 day after ICU discharge): Anxiety (Hospital Anxiety and Depression Scale: HADS & State Trait Anxiety Inventory-6: STAI-6)

- 1
2
3 7. Clinical outcomes (At discharge): a) length of ICU stay (ICU LOS) (or ward-ready), b)
4
5 Duration of mechanical ventilation/ proportion of mechanical ventilation-free days, c)
6
7 survival, d) hospital LOS and e) (3 months post-ICU discharge): 90-day survival.
- 8
9
10 8. Quality of life outcomes (6 weeks and 4 months post-ICU discharge): EuroQol Five
11
12 Dimensions Questionnaire (EQ-5DL), Short Form 36 Health Survey (SF-36)
- 13
14
15 9. Recollection and perception of the intervention (2-7 days after ICU discharge and 6
16
17 weeks post-ICU discharge): Qualitative open-ended questions to explore recollection of
18
19 intervention, views on intervention and acceptability (**Appendix 2**).

20 21 22 23 24 C. Feasibility

- 25
26 1. Acceptability: Number of patients refusing or wishing to discontinue a session.
27
28 Acceptability will be further assessed with the patients and clinicians advisory group.
- 29
30 2. Enrolment & consent: a) percentage (%) of eligible patients; reasons for non-
31
32 eligibility, b) time from admission to enrolment, c) recruitment rates, d) % of patients
33
34 declining consent
- 35
36 3. Randomization & concealment: a) time from enrolment to randomization, b) % of
37
38 cases at which allocation was inappropriately revealed; description of incident.
- 39
40 4. Protocol adherence & intervention fidelity: Percentage of: a) participants completing
41
42 the entire study protocol, b) sessions missed, interrupted, delayed; reasons. Adherence
43
44 to intervention protocol assessed by random observation audits, and by intervener's
45
46 detailed reports of any deviations from protocol and related reasons.
- 47
48 5. Data Collection & management: a) timeliness, accuracy of data collection, reliability,
49
50
51 b) testing of trial database, c) type, % of missing values, d) qualitative data on
52
53
54
55
56
57
58
59
60

1
2
3 participants' perceptions of the study, e) time required for all study procedures and
4
5 intervention (to be used in future economic assessment and assessment of burden of
6
7 the trial).
8
9

10 *Primary Feasibility criteria:*

11
12 The study will be considered feasible for the specific population and ICU context if the following
13
14 5 criteria are met:

- 15 a) Eligible patients declining consent < 60%
- 16 b) Cases at which allocation was inappropriately revealed < 3%
- 17 c) Participants withdrawing from study protocol while still in the ICU < 10%
- 18 d) Average sessions missed per patient < 40%
- 19 e) Average sessions interrupted per patient < 50%
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30

31 **Biomarker quantifications**

32 *Blood sampling*

33
34
35 One 5 ml blood sample will be collected in pre-coded general anti-coagulated vials, through an
36
37 intravascular catheter already in place, within 10 min before and 10 min after the intervention.
38
39

40 *Biomarker analyses*

41 a. Serum levels of HMGB-1, ACh and CRP.

42
43
44 These will be quantified by commercially available sandwich enzyme-linked immunosorbent
45
46 colorimetric assay (ELISA) kits (LifeSpan Biosciences, Seattle; WA, Biosource, S. Diego, CA; R
47
48 & D Systems, Minneapolis, MN, respectively). Intra- and inter-assay coefficients of variation (CV)
49
50 are expected to be less than 10%. All samples will be tested within the same assay run in duplicate
51
52
53
54
55
56
57

58 *REPOSE 18*

1
2
3 by a specialized laboratory technician. Measurements will be carried out at the Women's Health
4
5 Research Laboratory, Faculty of Nursing, University of Alberta.
6
7

8 *b. ANS (Autonomic Nervous System) activity: HF, LF AND LF/HF ratio*
9

10
11 ANS activity will be assessed through frequency domain analysis of electrocardiographic (ECG)
12
13 recordings. ECG recordings will be logged using the Zephyr™ BioModule™ and data will be
14
15 imported into the OmniSense™ software. Data from OmniSense™ will then be uploaded to
16
17 Kubios HRV software (Kubios HRV- Heart Rate Variability Analysis Software) and HF, LF and
18
19 LF/HF ratios will be computed. HRV data will be recorded continuously starting from 5 min
20
21 before, during and 5 min after the intervention. For ease of incorporation into statistical models,
22
23 HRV components will be analyzed at 5 minutes before the intervention, 5 minutes after the
24
25 intervention and several times during the intervention based on the timing of its various
26
27 components. Specifically, HRV components will be analyzed on the 8th and 15th minute
28
29 of massage (half-way and conclusion of massage), 3rd and 15th minute of RGI (induction and
30
31 conclusion of RGI), and end of music therapy.
32
33
34
35

36
37 **Data Analysis**

38
39 *Statistical Methods*

40
41
42 Demographic/ clinical characteristics of patients and all outcomes will be presented by treatment
43
44 group using descriptive statistics— mean (SD), median (IQR) or proportion. Outcomes will be
45
46 analyzed longitudinally over 5 days by logistic regression model based on generalized estimating
47
48 equations (GEE) with AR(1) correlation structure. ANCOVA, t-test or Mann-Whitney test, as
49
50 appropriate, will be conducted for the continuous outcomes that are not longitudinal. Models will
51
52 be adjusted for co-variates including pre-deliric score, administration of medication (sedatives,
53
54
55
56

1
2
3 analgesics, vasoactives and antipsychotics) and severity score (SOFA, APACHE). Chi-square or
4 exact test, as appropriate, will be used for categorical outcomes. We will treat pain outcomes as
5
6 both categorical (presence or absence of pain) and continuous variables (pain score). Confidence
7
8 intervals will be presented with estimated effects. Primary analysis will be based on all available
9
10 data utilizing data from all assessments. Since GEE assumes missing completely at random
11
12 (MCAR) mechanism, we plan to conduct a sensitivity analysis based on inverse probability
13
14 weighted GEE (IPWGEE) (30) which employs a less restrictive missing at random (MAR)
15
16 mechanism. A “last observation carried forward” (LOCF) approach was not considered because
17
18 analyzing all available data performs better than LOCF in GEE setting with respect to bias, Type
19
20 I error rate and coverage probability under both MCAR and MAR mechanisms. Although we are
21
22 not able to formally assess potential effects of the sham intervention with the current 2-group
23
24 design, GEE models will provide indications of such potential effects that will be taken into
25
26 account at a future trial. Analysis will be conducted by EPICORE.

27
28
29
30
31
32
33 To account for noncompliance, protocol deviations and missing outcomes, intention-to-treat (ITT)
34
35 analysis will be employed. ITT analysis includes every randomized subject according to treatment
36
37 assignment. Additionally, per protocol analysis will also be employed. Per-protocol (PP)
38
39 population is defined as a subset of the ITT population who completed the study without any major
40
41 protocol violations. If ITT and PP analyses lead to similar conclusions the reliability of results will
42
43 be supported. Although, this is a pilot trial, ITT will help reduce potential effects of selection bias.
44
45 PP analysis will assess whether the ITT result is too conservative. This will provide important data
46
47 regarding the effect size for the subsequent trial. Both analyses will assist us in revising the
48
49 protocol for the larger trial.

54 55 *Qualitative analyses*

56
57
58
59
60
REPOSE 20

1
2
3 Interview transcriptions will be thematically analyzed by an inductive content analysis approach
4
5 (31). A coding scheme will be developed based on recurrent themes of the first five interviews.
6
7 Subsequently, two researchers (EP, TP) will code independently, using axial and inductive coding
8
9 to formulate a final coding template by consensus. The final coding scheme will then be used to
10
11 code, compare and interpret all transcripts. Individual analyses of the team members will be
12
13 discussed to achieve shared understanding and to increase reliability. The data will be analyzed
14
15 via NVivo software (QSR International Doncaster, Victoria, Australia).
16
17
18
19

20 **Quality Control and Quality Assurance**

21
22
23 This pilot will be supervised by an independent trial steering committee (TSC), consisting of 3
24
25 clinical trial experts independent of the research team. Periodical audits of the intervention and
26
27 trial processes at both sites by personnel independent from investigators will be initiated by the
28
29 TSC. Randomization, recruitment, intervention adherence, blinding, stability and data collection
30
31 processes will be monitored. Trial Monitoring Committee (TMC) will also review relevant
32
33 information from similar studies and will consider the recommendations of the Data Monitoring
34
35 (DMC) and Ethics Committee. Study personnel have been trained to standardize processes. We
36
37 have developed two training videos including detailed demonstration of the intervention.
38
39 Moreover, research personnel involved with the intervention has received 18-21 hours of hands-
40
41 on training, including detailed auditing, and several hours of self-paced training to standardize the
42
43 process, communication and timing of intervention. Study personnel will meticulously record any
44
45 deviations from the intervention protocol to assess feasibility and effect on outcomes. Clinical data
46
47 will be retrieved from the quality-controlled clinical information system of the units. Detailed
48
49 electronic data collection forms with embedded quality controls will be used and reviewed in
50
51 detail. Data quality will be monitored through EPICORE before, during, and after entry. All data
52
53
54
55
56
57
58
59

REPOSE 21

1
2
3 will be entered electronically using study forms generated through RedCap® with embedded
4
5 quality control processes. Study data will be collected and managed using REDCap® electronic
6
7 data capture tools hosted at the University of Alberta (32). A quality control system will be applied
8
9 for biological measurements as per lab protocol. Day-to-day operations of the trial will be overseen
10
11 by a Trial Management Group (TMG) comprising, as a minimum, the Principal Investigator,
12
13 Senior Trial Manager, Trial Manager, Trial Statistician and Data Manager. TMG meetings will
14
15 take place on a regular basis throughout the duration of the study. The TMG will have
16
17 responsibility for ensuring the adherence and progress of the study in relation to all regulatory,
18
19 administrative academic and any clinical or safety issues.
20
21
22

23 24 **Ethics**

25
26
27 The protocol has received approval from the Human Research Ethics Board (HREB) University
28
29 of Alberta and administrative approvals from participating institutions. This study will be
30
31 conducted in compliance Canadian and International Good Clinical Practice standards. No
32
33 deviation from the protocol will be implemented without the prior review and approval of the
34
35 HREB except where it may be necessary to eliminate an immediate hazard to a research
36
37 participant. In such case, the deviation will be reported to the HREB.
38
39
40
41

42 Experienced research personnel not involved with the delivery of the intervention and in
43
44 patient care will acquire informed consent from legal surrogates or participants if competent to
45
46 consent. Participant assent will be acquired when participants regain capacity. Confidentiality,
47
48 anonymity and right to withdraw at any point with no questions asked and no effect on the quality
49
50 of care received will be assured. After completion of the study the data and samples will remain
51
52 stored at the academic institution for 5 years.
53
54
55
56
57

58 *REPOSE 22*

Confidentiality

Code-identified encrypted study data will be stored separately from participant information at an EPICORE database permitting code-access only. All study forms, lab specimens and data will be identified by an alphanumeric code to maintain confidentiality. Records that contain names, identifiers will be stored separately from study data identified by code. Participants' information will not be released outside the study. Participant information will be stored at an encrypted limited code-initiated access electronic file. Consent forms will be kept in a locked file cabinet at a pre-specified limited-access room, University of Alberta.

Safety

Although prior pilot data did not provide evidence of adverse effects or increased rate of complications, any physiological/ behavioural alteration during interventions will be recorded and analysed. Adverse events, irrespective of causal relationship, will be collected for all participants, during and up to half an hour after the intervention.

Data Dissemination

Results will be disseminated to participants, healthcare professionals, health services authorities and the public via conference presentations and publications. Results of this study will be used to inform the design and conduct of a future multi-center trial. The results of the trial will be presented at national and international meetings and published in peer-reviewed journals. A lay summary of the results will be available to trial participants on request. An online summary of the findings will also be made available.

REPOSE 23

Conclusions: This pilot clinical trial integrates a low-risk, patient-centered strategy, translational research and psychological outcomes to allow an evaluation of non-pharmacological delirium management with mechanistic insights. Implications of the definitive trial include the potential to reassure patients, decrease the incidence of frightening delirium experiences, and improve longitudinal outcomes.

References

1. Zaal IJ, Slooter AJ. Delirium in critically ill patients: epidemiology, pathophysiology, diagnosis and management. *Drugs* 2012; 72(11):1457-71.
2. Girard TD, Thompson JL, Pandharipande PP, Brummel NE, Jackson JC, Patel MB, Hughes CG, Chandrasekhar R, Pun BT, Boehm LM, Elstad MR, Goodman RB, Bernard GR, Dittus RS, Ely EW. Clinical phenotypes of delirium during critical illness and severity of subsequent long-term cognitive impairment: a prospective cohort study. *Lancet Respir Med*. 2018; 6(3):213-222.
3. Milbrandt EB, Deppen S, Harrison PL, et al., Costs associated with delirium in mechanically ventilated patients. *Crit Care Med* 2004; 32(4): 955-62.
4. Papathanassoglou E. Recent advances in understanding pain: What lies ahead for critical care? *Nurs Crit Care* 2014; 85(11):1586-93
5. Brame AL, Singer M. Stressing the obvious? An allostatic look at critical illness. *Crit Care Med* 2010; 38(10 Suppl):S600-7
6. Al-Qadheeb NS, Skrobik Y, Schumaker G, et al. Preventing ICU Subsyndromal Delirium Conversion to Delirium With Low-Dose IV Haloperidol: A Double-Blind, Placebo-Controlled Pilot Study. *Crit Care Med* 2016; 44(3):583-91

REPOSE 24

- 1
2
3 7. Su X, Meng ZT, Wu XH, Cui F, Li HL, Wang DX, Zhu X, Zhu SN, Maze M, Ma D.
4
5 Dexmedetomidine for prevention of delirium in elderly patients after non-cardiac surgery:
6
7 a randomised, double-blind, placebo-controlled trial. *Lancet*; 2016. 15;388(10054):1893-
8
9 1902. doi: 10.1016/S0140-6736(16)30580-3.
10
11
- 12 8. Barr J., Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of
13
14 pain, agitation, and delirium in adult patients in the intensive care unit. *Crit Care Med* 2013;
15
16 41(1): 263-306
17
18
- 19 9. Trogrlić Z, van der Jagt M, Bakker J, et al. A systematic review of implementation
20
21 strategies for assessment, prevention, and management of ICU delirium and their effect on
22
23 clinical outcomes. *Crit Care* 2015 ;19:157
24
25
- 26 10. Papathanassoglou, E. D., Giannakopoulou, M., Mpouzika, M., Bozas, E., Karabinis, A.
27
28 Potential effects of stress in critical illness through the role of stress neuropeptides. *Nurs*
29
30 *Crit Care* 2010; 15(4), 204-16.
31
32
- 33 11. Cuesta, J. M., Singer, M. The stress response and critical illness: A review. *Critical Care*
34
35 *Medicine* 2012; 40(12), 3283-9.
36
37
- 38 12. Norris, P. R., Ozdas, A., Cao, H., et al. Cardiac uncoupling and heart rate variability stratify
39
40 ICU patients by mortality: A study of 2088 trauma patients. *Ann Surg* 2006; 243(6), 804-
41
42 12.
43
44
- 45 13. Maclullich, A. M., Ferguson, K. J., Miller, T., de Rooij, S. E., & Cunningham, C.
46
47 Unravelling the pathophysiology of delirium: A focus on the role of aberrant stress
48
49 responses. *J Psychosom Res* 2008; 65(3), 229-38.
50
51
52
53
54
55
56
57

- 1
2
3
4 14. Zaal, I. J., Devlin. J. W., Peelen, L. M., Slooter, A. J. A systematic review of risk
5
6 factors for delirium in the ICU. *Crit Care Med* 2015; 43(1):40-7.
7
8 doi:10.1097/CCM.0000000000000625.
9
10
11
12 15. Brummel NE, Jackson JC, Pandharipande PP, Thompson JL, Shintani AK, Dittus RS, Gill
13
14 TM, Bernard GR, Ely EW, Girard TD. Delirium in the ICU and subsequent long-term
15
16 disability among survivors of mechanical ventilation. *Crit Care Med*. 2014;42(2):369-77.
17
18 doi: 10.1097/CCM.0b013e3182a645bd.
19
20
21 16. Oke, S. L., & Tracey, K. J. The inflammatory reflex and the role of complementary and
22
23 alternative medical therapies. *Ann NY Acad Sci* 2009; 1172, 172-80.
24
25
26 17. Park, E. R., Traeger, L., Vranceanu, A. M., et al. The development of a patient-centered
27
28 program based on the relaxation response: The Relaxation Response Resiliency Program
29
30 (3RP). *Psychosomatics* 2013; 54(2), 165-74.
31
32
33 18. Hadjibalassi, M., Lambrinou, E., Papastavrou, E., Papathanassoglou, E. The effect of
34
35 guided imagery on physiological and psychological outcomes of adult ICU patients: A
36
37 systematic literature review and methodological implications. *Austr Crit Care*. 2017; Mar
38
39 29. pii: S1036-7314(17)30164-9. doi: 10.1016/j.aucc.2017.03.001.
40
41
42 19. Chlan L, Halm MA. Does music ease pain and anxiety in the critically ill? *Am J Crit*
43
44 *Care*. 2013; 22(6):528-32.
45
46
47 20. Papathanassoglou E, Hadjibalassi M, Lambrinou E, Papastavrou E, Paikousis L,
48
49 Kyprianou T. Pilot Clinical Trial of the effects of an integrative nursing intervention on
50
51 critically ill patients' pain, hemodynamic measurements, psychological responses and
52
53 sleep. *Am J of Crit Care* 2018; 27:172-185.
54
55
56
57
58
59
60

- 1
2
3 21. Pan W. Sample size and power calculations with correlated binary data. *Control. Clin*
4
5 *Trials* 2001;22:211–27.
6
7
- 8 22. Moore CG, Carter RE, Nietert PJ, Stewart PW. Recommendations for planning pilot
9
10 studies in clinical and translational research. *Clin Transl Sci* 2011; 4(5):332-7
11
- 12 23. Hermann, C. Psychological interventions for chronic pediatric pain: State of the art, current
13
14 developments and open questions. *Pain Manag* 2011; 1(5), 473-83.
15
- 16 24. Dossey, B.M., & Keegan, L. *Holistic Nursing - A Handbook for Practice*. American
17
18 Holistic Nurses Association. Boston, MA: Jones & Bartlett, 2009.
19
- 20 25. Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M; Medical Research
21
22 Council Guidance. Developing and evaluating complex interventions: the new Medical
23
24 Council guidance. *BMJ*. 2008; 337:a1655.
25
26
- 27 26. Papathanassoglou ED. Psychological support and outcomes for ICU patients. *Nurs Crit*
28
29 *Care*. 2010;15(3):118-28.
30
31
- 32 27. Diego, M. A., & Field, T. Moderate pressure massage elicits a parasympathetic nervous
33
34 system response. *Int J Neurosci* 2009; 119(5), 630-8.
35
36
- 37 28. Neto AS, Nassar AP Jr, Cardoso SO, et al. Delirium screening in critically ill patients: a
38
39 systematic review and meta-analysis. *Crit Care Med* 2012; 40(6):1946-51.
40
41
- 42 29. Papathanassoglou E, Hadjibalassi M, Miltiadous P, Karanikola M. Effects of an
43
44 integrative relaxation intervention on inflammatory and stress biomarkers in critically ill
45
46 patients. *Critical Care Canada Forum* 2016, Toronto, ON, Canada.
47
48
49
50
51
52
53
54
55
56

- 1
2
3 30. Robins, J. M., Rotnitzky, A., & Zhao, L. P. Analysis of semiparametric regression models
4 for repeated outcomes in the presence of missing data. *J Am Stat Assoc* 1995; 90(429),
5 106-121.
6
7
8
9
10 31. Onwuegbuzie, A. J., Dickinson, W. B., Leech, N. L., & Zoran, A. G. A qualitative
11 framework for collecting and analyzing data in focus group research. *Int J Qual Meth* 2009;
12 Retrieved from: <http://creativecommons.org/licenses/by/2.0>
13
14
15 32. Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009).
16 Research Electronic Data Capture (REDCap) - A metadata-driven methodology and
17 workflow process for providing translational research informatics support. *J Biomed*
18 *Inform* 2009; 42(2), 377-81.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Contributions:** EDEP, YS, KH, JK contributed to study conception, design and manuscript
4 draft. HTS, CN, LR, SB, MM, TP contributed to discussions about design; EDEP, YS, KH, JK,
5
6 HTS, CN, LR, SB, MM, TP are investigators in the CIHR grant supporting this work. PT
7
8 contributed to refining data collection strategies. CL and RA contributed to the development and
9
10 teaching of the massage intervention and IH to randomization and statistical analysis plan. TSB
11
12 contributed to the development of the music therapy piece of the intervention. This study is
13
14 supported by the Canadian Critical Care Trials group. All authors contributed to refinement of
15
16 the study protocol and approved the final manuscript.
17
18
19
20
21

22 **Funding:** This work is supported by a Canadian Institutes of Health Research (CIHR) grant
23
24 (CIHR PS 148850; PI: EP) and an Alberta Innovates Strategy for Patient Oriented Research
25
26 (SPOR) Support Grant (PI: EP)
27
28
29

30 **Sponsors's contact data:** Canadian Institutes of Health Research, 160 Elgin Street, 9th Floor
31
32 Address Locator 4809A, Ottawa ON K1A 0W9, Canada; Tel.: 613-941-2672.
33
34

35 Alberta Innovates- SPOR Support: 1500, 10104 – 103 Avenue, Edmonton, Alberta, T5J 0H8,
36
37 Canada; Tel.: 780-423-5727.
38

39 **Acknowledgements:** The authors are grateful to the participating sites: Royal Alexandra
40
41 Hospital, Edmonton, AB, Canada and University of Alberta Hospital, General Systems ICU,
42
43 Edmonton, AB, Canada. We would like to acknowledge the support of the Consultation and
44
45 Research Services Platform at The Alberta' SPOR SUPPORT Unit in the statistical services. We
46
47 wish to thank the Epidemiology Coordinating Research Centre (EPICORE), University of
48
49 Alberta, for statistics consultation, and Lily Yushko, systems analyst EPICORE for development
50
51
52
53
54
55
56
57
58
59
60

1
2
3 of patient report forms, and Thilini Herath Mudiyansele for contributions to the final version
4
5 of the manuscript.
6
7

8 **Authors' conflict of interest:** None declared
9

10
11 **Data Statement:** Technical appendix, statistical code, and dataset will be available from
12
13 EPICORE, University of Alberta.
14
15

16 17 18 19 **Legends**

20 21 **Figure 1.**

22
23 Evidence-based framework for the physiological mechanism implicated in relaxation-induced
24
25 effects in critical illness. Relaxation acts early at the pathophysiological cascade through which an
26
27 exaggerated stress response results in pro-inflammatory effects, suppressed PNS outflow and
28
29 subsequently in systemic inflammation, multiple organ dysfunction and death. The relaxation
30
31 response counterbalances the exaggerated stress response and activates PNS and cholinergic anti-
32
33 inflammatory signaling, which downregulates pro-inflammatory (e.g., HMGB-1) and up-regulates
34
35 anti-inflammatory cytokines; therefore attenuating systemic inflammation and its detrimental
36
37 organ effects. (*$\alpha 7$ -nAChR: alpha7- nicotinic acetylcholine receptor, HMGB-1: High Mobility*
38
39 *Group Box-1; PNS: Parasympathetic Nervous System*)
40
41
42
43
44
45
46
47


48 **Figure 2:**

49
50 **Schematic of study design.** (*Ach: Acetylcholine, AE: Adverse Event, APACHE: Acute*
51
52 *Physiology & Chronic Health Evaluation, CPOT: Critical Care Pain Observation Tool, CRP: C-*
53
54 *Reactive Protein, EQ-5D: EuroQol Five Dimensions Questionnaire, HADS: Hospital Anxiety*
55
56


57
58
59
60
REPOSE 30

1
2
3 *and Depression Scale, HF: High Frequency, HMGB: High Mobility Group Box, HRV: Heart*
4 *Rate Variability, ICDSC: Intensive Care Delirium Screening Checklist, ICU: Intensive Care*
5 *Unit, IQCODE: Informant Questionnaire on Cognitive Decline in the Elderly, IV: Intravenous,*
6 *LF: Low Frequency, LOS : Length of Stay, NRS: Numeric Rating Scale, RASS: Richmond*
7 *Agitation Sedation Scale, RGI: Relaxation and Guided Imagery, S-R: Self-Reported, SOFA:*
8 *Sequential Organ Failure, STAI: State Trait Anxiety Inventory).*
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



279x361mm (300 x 300 DPI)



279x361mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Primary Outcome: ICDSC≥4													
Secondary outcomes: ICDSC, ICDSC:1-3, RASS, daily sedatives/ analgesics/ antipsychotics dose, sleep NRS, sleep duration, APACHE II, SOFA	X	X	X	X	X	X	X						
		pre-post-Intervention											
C-POT, PAIN NRS, pain distress NRS, stress NRS, HF- LF HRV	X	X2	X2	X2	X2	X2							
		pre-post-Intervention											
HMGB-1, CRP, Ach		X2	X2	X2	X2	X2							
ICU LOS, duration MV, ICU survival								X					
HADS									X				
Hospital survival, Hospital LOS										X			
											X		

136/bmjopen-2018-023961 on 15 January 2019. Downloaded from <http://bmjopen.bmj.com/> on April 27, 2024 by guest. Protected by copyright.

<p>6 week survival, Interview, EQ-5D, SF-36</p>													
<p>4-month survival, EQ-5D, SF-36</p>													X

Ach: Acetylcholine, CPOT: Critical Care Pain Observation Tool, CRP: C-Reactive Protein, DEMMI: de Morton Mobility Index, EQ-5D: EuroQol Five Dimensions Questionnaire, HADS: Hospital Anxiety and Depression Scale, HF: High Frequency, HMGB: High Mobility Group Box, HRV: Heart Rate Variability, ICDSC: Intensive Care Delirium Screening Checklist, ICU: Intensive Care Unit, Interview: Qualitative open ended questions; IQCODE: Informant Questionnaire on Cognitive Decline in the Elderly, LF: Low Frequency, LOS : Length of Stay, MV: mechanical ventilation, NRS: Numeric Rating Scale, RASS: Richmond Agitation Sedation Scale, RGI: Relaxation and Guided Imagery, S-R: Self-Reported, SOFA: Sequential Organ Failure, STAI: State Trait Anxiety Inventory.

For Peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

1
2
3 **Appendix 2.** Telephone interview guide (Qualitative open-ended questions)
4
5
6
7
8

- 9 1. Do you remember listening to music while in the ICU? Can you describe what
10 remember?
11
12
13 2. Do you remember listening to a voice through the headphones? Can you describe what
14 you remember?
15
16
17 3. If yes, how did this make you feel? Were you able to follow the instructions with your
18 mind/ imagination? Please describe
19
20
21 4. Do you remember somebody giving you a massage? Can you describe what you
22 remember?
23
24
25 5. If yes, how did this make you feel?
26
27
28 6. Would you wish to receive this intervention again? Why?
29
30
31 7. Would you recommend this intervention for other patients? Why?
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

		Reporting Item	Page Number
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	2
Protocol version	#3	Date and version identifier	2
Funding	#4	Sources and types of financial, material, and other support	22
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	22
Roles and	#5b	Name and contact information for the trial sponsor	22

1	responsibilities:			
2	sponsor contact			
3	information			
4				
5	22Roles and	#5c	Role of study sponsor and funders, if any, in study	22
6	responsibilities:		design; collection, management, analysis, and	
7	sponsor and funder		interpretation of data; writing of the report; and the	
8			decision to submit the report for publication,	
9			including whether they will have ultimate authority	
10			over any of these activities	
11				
12				
13				
14				
15	Roles and	#5d	Composition, roles, and responsibilities of the	14-15
16	responsibilities:		coordinating centre, steering committee, endpoint	
17	committees		adjudication committee, data management team,	
18			and other individuals or groups overseeing the	
19			trial, if applicable (see Item 21a for data	
20			monitoring committee)	
21				
22				
23				
24				
25	Background and	#6a	Description of research question and justification	4-5
26	rationale		for undertaking the trial, including summary of	
27			relevant studies (published and unpublished)	
28			examining benefits and harms for each	
29			intervention	
30				
31				
32				
33	Background and	#6b	Explanation for choice of comparators	5
34	rationale: choice of			
35	comparators			
36				
37				
38	Objectives	#7	Specific objectives or hypotheses	5, 6
39				
40				
41	Trial design	#8	Description of trial design including type of trial	5
42			(eg, parallel group, crossover, factorial, single	
43			group), allocation ratio, and framework (eg,	
44			superiority, equivalence, non-inferiority,	
45			exploratory)	
46				
47				
48				
49	Study setting	#9	Description of study settings (eg, community clinic,	6
50			academic hospital) and list of countries where	
51			data will be collected. Reference to where list of	
52			study sites can be obtained	
53				
54				
55				
56	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If	7
57			applicable, eligibility criteria for study centres and	
58				
59				
60				

		individuals who will perform the interventions (eg, surgeons, psychotherapists)	
Interventions: description	#11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	7-8,9
Interventions: modifications	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	8
Interventions: adherence	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	8
Interventions: concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	9
Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	10-12
Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	1. Appendix
Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	6-7
Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size	6
Allocation:	#16a	Method of generating the allocation sequence (eg,	8

1	sequence		computer-generated random numbers), and list of	
2	generation		8any factors for stratification. To reduce	
3			predictability of a random sequence, details of any	
4			planned restriction (eg, blocking) should be	
5			provided in a separate document that is	
6			unavailable to those who enrol participants or	
7			assign interventions	
8				
9				
10				
11	Allocation	#16b	Mechanism of implementing the allocation	8
12	concealment		sequence (eg, central telephone; sequentially	
13	mechanism		numbered, opaque, sealed envelopes), describing	
14			any steps to conceal the sequence until	
15			interventions are assigned	
16				
17				
18				
19	Allocation:	#16c	Who will generate the allocation sequence, who	8
20	implementation		will enrol participants, and who will assign	
21			participants to interventions	
22				
23				
24				
25	Blinding (masking)	#17a	Who will be blinded after assignment to	8-9
26			interventions (eg, trial participants, care providers,	
27			outcome assessors, data analysts), and how	
28				
29				
30	Blinding (masking):	#17b	If blinded, circumstances under which unblinding	9, NA
31	emergency		is permissible, and procedure for revealing a	
32	unblinding		participant's allocated intervention during the trial	
33				
34				
35				
36	Data collection plan	#18a	Plans for assessment and collection of outcome,	9-10
37			baseline, and other trial data, including any related	
38			processes to promote data quality (eg, duplicate	
39			measurements, training of assessors) and a	
40			description of study instruments (eg,	
41			questionnaires, laboratory tests) along with their	
42			reliability and validity, if known. Reference to	
43			where data collection forms can be found, if not in	
44			the protocol	
45				
46				
47				
48				
49				
50	Data collection	#18b	Plans to promote participant retention and	9
51	plan: retention		complete follow-up, including list of any outcome	
52			data to be collected for participants who	
53			discontinue or deviate from intervention protocols	
54				
55				
56				
57	Data management	#19	Plans for data entry, coding, security, and storage,	9,15
58			including any related processes to promote data	
59				
60				

1		quality (eg, double data entry; range checks for	
2		data values). Reference to where details of data	
3		management procedures can be found, if not in	
4		the protocol	
5			
6			
7	Statistics:	#20a Statistical methods for analysing primary and	13-14
8	outcomes	secondary outcomes. Reference to where other	
9		details of the statistical analysis plan can be	
10		found, if not in the protocol	
11			
12			
13			
14	Statistics: additional	#20b Methods for any additional analyses (eg, subgroup	13-14
15	analyses	and adjusted analyses)	
16			
17	Statistics: analysis	#20c Definition of analysis population relating to	14
18	population and	protocol non-adherence (eg, as randomised	
19	missing data	analysis), and any statistical methods to handle	
20		missing data (eg, multiple imputation)	
21			
22			
23			
24	Data monitoring:	#21a Composition of data monitoring committee (DMC);	14-15
25	formal committee	summary of its role and reporting structure;	
26		statement of whether it is independent from the	
27		sponsor and competing interests; and reference to	
28		where further details about its charter can be	
29		found, if not in the protocol. Alternatively, an	
30		explanation of why a DMC is not needed	
31			
32			
33			
34			
35			
36	Data monitoring:	#21b Description of any interim analyses and stopping	NA
37	interim analysis	guidelines, including who will have access to	
38		these interim results and make the final decision	
39		to terminate the trial	
40			
41			
42	Harms	#22 Plans for collecting, assessing, reporting, and	16
43		managing solicited and spontaneously reported	
44		adverse events and other unintended effects of	
45		trial interventions or trial conduct	
46			
47			
48			
49	Auditing	#23 Frequency and procedures for auditing trial	8,15
50		conduct, if any, and whether the process will be	
51		independent from investigators and the sponsor	
52			
53			
54	Research ethics	#24 Plans for seeking research ethics committee /	15,16
55	approval	institutional review board (REC / IRB) approval	
56			
57			
58	Protocol	#25 Plans for communicating important protocol	15
59			
60			

1	amendments		modifications (eg, changes to eligibility criteria,	
2			outcomes, analyses) to relevant parties (eg,	
3			investigators, REC / IRBs, trial participants, trial	
4			registries, journals, regulators)	
5				
6				
7	Consent or assent	#26a	Who will obtain informed consent or assent from	15-16
8			potential trial participants or authorised	
9			surrogates, and how (see Item 32)	
10				
11				
12	Consent or assent:	#26b	Additional consent provisions for collection and	16
13	ancillary studies		use of participant data and biological specimens in	
14			ancillary studies, if applicable	
15				
16				
17	Confidentiality	#27	How personal information about potential and	16
18			enrolled participants will be collected, shared, and	
19			maintained in order to protect confidentiality	
20			before, during, and after the trial	
21				
22				
23				
24	Declaration of	#28	Financial and other competing interests for	22
25	interests		principal investigators for the overall trial and each	
26			study site	
27				
28				
29				
30	Data access	#29	Statement of who will have access to the final trial	NA
31			dataset, and disclosure of contractual agreements	
32			that limit such access for investigators	
33				
34				
35	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care,	NA
36	trial care		and for compensation to those who suffer harm	
37			from trial participation	
38				
39				
40	Dissemination	#31a	Plans for investigators and sponsor to	16
41	policy: trial results		communicate trial results to participants,	
42			healthcare professionals, the public, and other	
43			relevant groups (eg, via publication, reporting in	
44			results databases, or other data sharing	
45			arrangements), including any publication	
46			restrictions	
47				
48				
49				
50				
51	Dissemination	#31b	Authorship eligibility guidelines and any intended	NA
52	policy: authorship		use of professional writers	
53				
54				
55	Dissemination	#31c	Plans, if any, for granting public access to the full	16
56	policy: reproducible		protocol, participant-level dataset, and statistical	
57	research		code	
58				
59				
60				

1 2 3 4 5	Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	Upon request
6 7 8 9 10 11 12	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	12-13 & upon request

The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)